<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults - Law, S - 2016 | Cochrane Library</title> <meta content="Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults - Law, S - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008541.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults - Law, S - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008541.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008541.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults" name="citation_title"/> <meta content="Simon Law" name="citation_author"/> <meta content="The Churchill Hospital" name="citation_author_institution"/> <meta content="Sheena Derry" name="citation_author"/> <meta content="sheena.derry@retired.ox.ac.uk" name="citation_author_email"/> <meta content="R Andrew Moore" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD008541.pub3" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/04/20" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008541.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008541.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008541.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acute Disease; Anti-Inflammatory Agents, Non-Steroidal [*therapeutic use]; Drug Combinations; Drug Therapy, Combination [methods]; Migraine Disorders [*drug therapy]; Naproxen [*therapeutic use]; Randomized Controlled Trials as Topic; Serotonin 5-HT1 Receptor Agonists [*therapeutic use]; Sumatriptan [*administration &amp; dosage]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008541.pub3&amp;doi=10.1002/14651858.CD008541.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008541.pub3&amp;doi=10.1002/14651858.CD008541.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008541.pub3&amp;doi=10.1002/14651858.CD008541.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008541.pub3&amp;doi=10.1002/14651858.CD008541.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008541.pub3&amp;doi=10.1002/14651858.CD008541.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008541.pub3&amp;doi=10.1002/14651858.CD008541.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008541.pub3&amp;doi=10.1002/14651858.CD008541.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008541.pub3&amp;doi=10.1002/14651858.CD008541.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008541.pub3&amp;doi=10.1002/14651858.CD008541.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008541.pub3&amp;doi=10.1002/14651858.CD008541.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008541.pub3&amp;doi=10.1002/14651858.CD008541.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008541.pub3&amp;doi=10.1002/14651858.CD008541.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008541.pub3&amp;doi=10.1002/14651858.CD008541.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008541.pub3&amp;doi=10.1002/14651858.CD008541.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008541.pub3&amp;doi=10.1002/14651858.CD008541.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008541.pub3&amp;doi=10.1002/14651858.CD008541.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008541.pub3&amp;doi=10.1002/14651858.CD008541.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008541.pub3&amp;doi=10.1002/14651858.CD008541.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008541.pub3&amp;doi=10.1002/14651858.CD008541.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008541.pub3&amp;doi=10.1002/14651858.CD008541.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008541.pub3&amp;doi=10.1002/14651858.CD008541.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008541.pub3&amp;doi=10.1002/14651858.CD008541.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008541.pub3&amp;doi=10.1002/14651858.CD008541.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="VXKc2U6b";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008541\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008541\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008541\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008541\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ru","ms","hr","fa","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008541.pub3",title:"Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults",firstPublishedDate:"Apr 20, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=VXKc2U6b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008541.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008541.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008541.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008541.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008541.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008541.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008541.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008541.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008541.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008541.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>10138 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008541.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008541.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008541.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008541.pub3/full#CD008541-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008541.pub3/full#CD008541-sec-0086"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008541.pub3/full#CD008541-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008541.pub3/full#CD008541-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008541.pub3/full#CD008541-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008541.pub3/full#CD008541-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008541.pub3/full#CD008541-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008541.pub3/full#CD008541-sec-0080"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008541.pub3/appendices#CD008541-sec-0098"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/table_n/CD008541StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/table_n/CD008541StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008541.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008541.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008541.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008541.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008541.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008541.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008541.pub3/information#CD008541-cr-0004">Simon Law</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008541.pub3/information#CD008541-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Sheena Derry</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008541.pub3/information#CD008541-cr-0006">R Andrew Moore</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/information/en#CD008541-sec-0113">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 20 April 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008541.pub3">https://doi.org/10.1002/14651858.CD008541.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008541-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008541-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008541-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008541-abs-0008">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008541-abs-0001" lang="en"> <section id="CD008541-sec-0001"> <h3 class="title" id="CD008541-sec-0001">Background</h3> <p>This is an updated version of the original Cochrane review published in October 2013 on 'Sumatriptan plus naproxen for acute migraine attacks in adults'. </p> <p>Migraine is a common disabling condition and a burden for the individual, health services, and society. It affects two to three times more women than men, and is most common in the age range 30 to 50 years. Effective abortive treatments include the triptan and non‐steroidal anti‐inflammatory classes of drugs. These drugs have different mechanisms of action and combining them may provide better relief. Sumatriptan plus naproxen is now available in combination form for the acute treatment of migraine. </p> </section> <section id="CD008541-sec-0002"> <h3 class="title" id="CD008541-sec-0002">Objectives</h3> <p>To determine the efficacy and tolerability of sumatriptan plus naproxen, administered together as separate tablets or taken as a fixed‐dose combination tablet, compared with placebo and other active interventions in the treatment of acute migraine attacks in adults. </p> </section> <section id="CD008541-sec-0003"> <h3 class="title" id="CD008541-sec-0003">Search methods</h3> <p>For this update we searched the Cochrane Central Register of Controlled Trials (CENTRAL) via <i>The Cochrane Register of Studies Online</i> (CRSO) to 28 October 2015, MEDLINE (via Ovid) from 1946 to 28 October 2015, and EMBASE (via Ovid) from 1974 to 28 October 2015, and two online databases (www.gsk‐clinicalstudyregister.com and www.clinicaltrials.gov). We also searched the reference lists of included studies and relevant reviews. </p> </section> <section id="CD008541-sec-0004"> <h3 class="title" id="CD008541-sec-0004">Selection criteria</h3> <p>We included randomised, double‐blind, placebo‐ or active‐controlled studies, with at least 10 participants per treatment arm, using sumatriptan plus naproxen to treat a migraine headache episode. </p> </section> <section id="CD008541-sec-0005"> <h3 class="title" id="CD008541-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trial quality and extracted data. We used numbers of participants achieving each outcome to calculate risk ratio and numbers needed to treat for an additional beneficial outcome (NNT) or for an additional harmful outcome (NNH) compared with placebo or a different active treatment. </p> </section> <section id="CD008541-sec-0006"> <h3 class="title" id="CD008541-sec-0006">Main results</h3> <p>For this update we identified one new study (43 participants), but it did not contribute any data for analysis. The review included 13 studies using sumatriptan 85 mg or 50 mg plus naproxen 500 mg to treat attacks of mild, moderate, or severe pain intensity. Twelve studies contributed data for analyses: 3663 participants received combination treatment, 3682 placebo, 964 sumatriptan, and 982 naproxen. We judged only one small study to be at high risk of bias for any of the criteria evaluated; it did not contribute to any analyses. </p> <p>Overall, the combination was better than placebo for the primary outcomes of pain‐free and headache relief at two hours. The NNT for pain‐free at two hours was 3.1 (95% confidence interval 2.9 to 3.5) when the baseline pain was mild (50% response with sumatriptan plus naproxen compared with 18% with placebo), and 4.9 (4.3 to 5.7) when baseline pain was moderate or severe (28% with sumatriptan plus naproxen compared with 8% with placebo) (high quality evidence). Using 50 mg of sumatriptan, rather than 85 mg, in the combination did not significantly change the result. Treating early, when pain was still mild, was significantly better than treating once pain was moderate or severe for pain‐free responses at two hours and during the 24 hours post dose. Adverse events were mostly mild or moderate in severity and rarely led to withdrawal; they were more common with the combination than with placebo (moderate quality evidence). </p> <p>Where the data allowed direct comparison, combination treatment was superior to either monotherapy, but adverse events were less frequent with naproxen than with sumatriptan (moderate quality evidence). </p> </section> <section id="CD008541-sec-0007"> <h3 class="title" id="CD008541-sec-0007">Authors' conclusions</h3> <p>The conclusions of this review were not changed. Combination treatment was effective in the acute treatment of migraine headaches. The effect was greater than for the same dose of either sumatriptan or naproxen alone, but additional benefits over sumatriptan alone were not large. More participants achieved good relief when medication was taken early in the attack, when pain was still mild. Adverse events were more common with the combination and sumatriptan alone than with placebo or naproxen alone. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008541-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008541-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD008541-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD008541-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008541-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008541-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008541-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD008541-abs-0010">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008541-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD008541-abs-0004">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008541-abs-0002" lang="en"> <h3>Sumatriptan plus naproxen for acute migraine attacks in adults</h3> <p><b>Bottom line</b> </p> <p>The combination of sumatriptan plus naproxen was useful for treating migraine attacks in the studies we found. It was not a lot better than using sumatriptan alone, but it was much better than using naproxen alone. Attacks were more successfully treated when medication was taken early, when pain was mild. </p> <p><b>Background</b> </p> <p>Migraine is a complex condition with a wide variety of symptoms. It affects two to three times more women than men, and is most common in the age range 30 to 50 years. For many people, the main feature is a painful headache. Other symptoms include disturbed vision; sensitivity to light, sound, and smells; feeling sick; and vomiting. </p> <p>Both nonsteroidal anti‐inflammatory drugs (NSAIDs) and the triptan class of drugs are used to treat migraine headaches. This review examined how well naproxen (an NSAID) and sumatriptan (a triptan) work when combined. The combination tablet is not available in most countries, but separate tablets are widely available and can be taken together. </p> <p><b>Study characteristics</b> </p> <p>On 28 October 2015, we looked for clinical trials using sumatriptan plus naproxen to treat migraine headache in adults. People were given either a combination of sumatriptan and naproxen, sumatriptan only, naproxen only, or a placebo (dummy) treatment. They did not know which treatment they were taking, and nor did the health professionals looking after them. </p> <p><b>Key results</b> </p> <p>We found 13 studies, of which 12 (with about 9300 people) provided information on how well the combination treatment worked. </p> <p>The combination of sumatriptan plus naproxen was better than placebo for relieving acute migraine attacks in adults. When the starting headache intensity was mild, 5 in 10 (50%) of people treated with the combination were pain‐free at two hours compared with about 2 in 10 (18%) with placebo. Almost 6 in 10 (58%) people with moderate or severe pain who were treated with the combination had pain reduced to mild or none at two hours, compared with 3 in 10 (27%) with placebo. The combination was also better than the same dose of either drug given alone in these people. Results were 5 in 10 (52%) people with sumatriptan alone or about 4 in 10 (44%) with naproxen alone. </p> <p>The combination was better than placebo or either drug alone for relief of other migraine symptoms (nausea, sensitivity to light or sound) and loss of ability to function normally. Adverse events of dizziness, tingling or burning of the skin, sleepiness (somnolence), nausea, indigestion (dyspepsia), dry mouth, and chest discomfort were more common with sumatriptan (alone or in combination) than with placebo or naproxen. They were generally of mild to moderate severity and rarely led to withdrawal from the studies. </p> <p><b>Quality of the evidence</b> </p> <p>The studies were carried out to high standards and were generally large enough to give reliable results, so that most of the results for efficacy were of high quality. Results for adverse events were downgraded to moderate quality because there were fewer events. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008541-sec-0086" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008541-sec-0086"></div> <h3 class="title" id="CD008541-sec-0087">Implications for practice</h3> <section id="CD008541-sec-0087"> <section id="CD008541-sec-0088"> <h5 class="title">For people with migraine</h5> <p>The combination of sumatriptan plus naproxen is better than naproxen alone, and probably better than sumatriptan alone. It is not clear whether there is any clinical significance to the benefits observed with the combination over sumatriptan alone. More people get good relief when medication is taken early in the attack, when pain is still mild. Adverse events are more common with the combination and sumatriptan alone than with placebo or naproxen alone, but these events do not usually stop people from taking the medicine. </p> <p>The combination tablet is not available in most countries, but the individual components are widely available and can be taken together. </p> </section> <section id="CD008541-sec-0089"> <h5 class="title">For clinicians</h5> <p>The combination of sumatriptan plus naproxen provides good levels of relief to more people than either drug alone, but the clinical significance of the benefits observed with the combination over sumatriptan alone are unclear. More people get good relief when medication is taken early in the attack, when pain is still mild, so early treatment should be encouraged. Adverse events are more common with the combination and sumatriptan alone than with placebo or naproxen alone, but these events rarely led to withdrawal in these studies. </p> <p>The combination tablet is not available in many countries outside the US, but the components as separate tablets can be taken simultaneously, although sumatriptan alone is available only in 50 and 100 mg doses. The included study using separate tablets used the 50 mg dose. </p> </section> <section id="CD008541-sec-0090"> <h5 class="title">For policy makers</h5> <p>No single treatment provides a good response in all people with migraine. Combining two drugs with different actions is a rational option to increase the number who benefit, and the combination of sumatriptan with naproxen does provide good outcomes to more people than either drug alone, without compromising tolerability, although the benefits over sumatriptan alone are small. As with monotherapy, early treatment with this combination gives better results and should be promoted. </p> <p>The combination tablet is not available in most countries outside the US, but the components as separate tablets can be taken simultaneously, although sumatriptan alone is available only in 50 and 100 mg doses. The included study using separate tablets used the 50 mg dose. </p> </section> <section id="CD008541-sec-0091"> <h5 class="title">For funders</h5> <p>The combination of sumatriptan with naproxen provides good outcomes to more people than either drug alone, without compromising tolerability, although the benefits over sumatriptan alone are small. The combination tablet is not available in many countries outside the US, but the components as separate tablets can be taken simultaneously, although sumatriptan alone is available only in 50 and 100 mg doses. The included study using separate tablets used the 50 mg dose. Using separate tablets may be less convenient, but is considerably less costly. </p> </section> </section> <h3 class="title" id="CD008541-sec-0092">Implications for research</h3> <section id="CD008541-sec-0092"> <section id="CD008541-sec-0093"> <h5 class="title">General</h5> <p>Migraine is common and debilitating. Combining two drugs with different modes of action to treat migraine offers the opportunity to target different components of migraine pathophysiology. It may also be possible to achieve a good response with lower doses of one or both drugs. </p> <p>These studies combining sumatriptan with naproxen demonstrate better results than either drug alone, but studies are needed to determine which triptan and which NSAID make the best combination, and for whom. To date there are few published trials of different combinations. Naproxen 500 mg is of limited efficacy when used as a monotherapy in migraine when pain is moderate or severe. Ibuprofen 400 mg and diclofenac 50 mg produce lower (better) NNTs, and may be more appropriate nonsteroidal anti‐inflammatory drugs to be used in combination with a triptan. </p> <p>Including a broader spectrum of people with migraine‐like headaches, some of whom may not fulfil IHS criteria for migraine, could increase the generalisability of study results, and help to identify subpopulations who respond differently. </p> </section> <section id="CD008541-sec-0094"> <h5 class="title">Design</h5> <p>The design of the trials is good, and major changes appear unnecessary.</p> </section> <section id="CD008541-sec-0095"> <h5 class="title">Measurement (endpoints)</h5> <p>Clinically useful outcomes in migraine trials are well established, but part of the reason for investigating drug combinations is to achieve earlier responses and to reduce recurrence of the headache, which is not uncommon. This requires both routine measurement and reporting of outcomes at earlier (eg at half‐ and one‐hour) and later (eg at 24‐ and 48‐hour) time points. </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008541-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008541-sec-0008"></div> <div class="table" id="CD008541-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Sumatriptan 50 mg or 85 mg plus naproxen 500 mg compared with placebo for migraine headache</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Sumatriptan 50 mg or 85 mg plus naproxen 500 mg compared with placebo for migraine headache</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: adults with migraine headache ‐ moderate or severe and mild baseline pain</b> </p> <p><b>Settings: community</b> </p> <p><b>Intervention: sumatriptan 50 mg or 85 mg plus naproxen 500 mg</b> </p> <p><b>Comparison: placebo</b> </p> </td> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Probable outcome with</b> <br/><b>comparator</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>Probable outcome with</b> <br/><b>intervention</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>NNT or NNH</b> <br/><b>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>No. of studies, attacks, events</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain‐free response at 2 h for moderate to severe baseline pain</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.7 (2.8 to 4.5)</p> <p>NNT 4.9 (4.3 to 5.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies, 2596 attacks, 462 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate numbers of studies and attacks, study quality good, consistency of response</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain‐free response at 2 h for mild baseline pain</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>180 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.8 (2.4 to 3.1)</p> <p>NNT 3.1 (2.9 to 3.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 studies, 3395 attacks, 1252 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate numbers of studies and attacks, study quality good, consistency of response</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Headache relief at 2 h for moderate to severe baseline pain</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>270 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>580 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.2 (2.0 to 2.4)</p> <p>NNT 3.2 (2.9 to 3.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies, 2596 attacks, 1107 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate numbers of studies and attacks, study quality good, consistency of response</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sustained pain‐free during the 24 h post dose for moderate to severe baseline pain</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.4 (2.7 to 4.4)</p> <p>NNT 7.9 (5.9 to 8.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies, 2596 attacks, 339 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate numbers of studies and attacks, study quality good, consistency of response. Downgraded because of threat from potential publication bias with modest effect size and modest number of events </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sustained pain‐free during the 24 h post dose for mild baseline pain</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>370 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.0 (2.6 to 3.6)</p> <p>NNT 4.1 (3.7 to 4.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 studies, 3396 attacks, 907 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate numbers of studies and attacks, study quality good, consistency of response</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sustained headache relief during the 24 h post dose for moderate or severe baseline pain</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>160 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>430 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.6 (2.3 to 3.0)</p> <p>(NNT 3.8 (3.4 to 4.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies, 2596 attacks, 768 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate numbers of studies and attacks, study quality good, consistency of response</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>At least 1 AE during treatment for moderate to severe baseline pain</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>210 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.0 (1.6 to 2.4)</p> <p>NNH 11 (8.3 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies, 2793 attacks, 465 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate numbers of studies and attacks, study quality good, consistency of response. Downgraded because of threat from potential publication bias with modest effect size </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>At least 1 AE during treatment for mild baseline pain</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>140 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.5 (1.2 to 1.9)</p> <p>NNH 18 (13 to 30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 studies, 2823 attacks, 329 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate numbers of studies and attacks, study quality good, consistency of response. Downgraded because of threat from potential publication bias with modest effect size and modest number of events </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious AE (all levels of baseline pain)</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 event possibly related to intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>AE:</b> adverse event; <b>CI:</b> confidence interval; <b>NNT:</b> number needed to treat for an additional beneficial outcome; <b>NNH:</b> number needed to treat for an additional harmful outcome; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008541-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008541-sec-0009"></div> <p>This is an update of a review first published in October 2013 (<a href="./references#CD008541-bbs2-0072" title="LawS , DerryS , MooreRA . Sumatriptan plus naproxen for acute migraine attacks in adults. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD008541.pub2]">Law 2013a</a>). </p> <section id="CD008541-sec-0010"> <h3 class="title" id="CD008541-sec-0010">Description of the condition</h3> <p>Migraine is a common, disabling headache disorder, ranked seventh highest among specific causes of disability globally (<a href="./references#CD008541-bbs2-0064" title="SteinerTS , StovnerLJ , BirbeckGL . Migraine: the seventh disabler. Journal of Headache and Pain2013;14:1. [DOI: 10.1186/1129-2377-14-1]">Steiner 2013</a>), and with considerable social and economic impact (<a href="./references#CD008541-bbs2-0037" title="HazardE , MunakataJ , BigalME , RupnowMF , LiptonRB . The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis. Value in Health2009;12(1):55-64. [DOI: 10.1111/j.1524-4733.2008.00404.x]">Hazard 2009</a>). Recent reviews found a one‐year prevalence of 15% globally (<a href="./references#CD008541-bbs2-0069" title="VosT , FlaxmanAD , NaghaviM , LozanoR , MichaudC , EzzatiM , et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet2012;380(9859):2163-96. [DOI: 1016/S0140-6736(12)61729-2]">Vos 2012</a>) and for adults in European countries (<a href="./references#CD008541-bbs2-0065" title="StovnerLJ , AndreeC . Prevalence of headache in Europe: a review for the Eurolight project. Journal of Headache and Pain2010;11(4):289-99. [DOI: 10.1007/s10194-010-0217-0]">Stovner 2010</a>), 13% for all ages in the USA (<a href="./references#CD008541-bbs2-0068" title="VictorTW , HuX , CampbellJC , BuseDC , LiptonRB . Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia2010;30(9):1065-72. [DOI: 10.1177/0333102409355601]">Victor 2010</a>), 21% in Russia (<a href="./references#CD008541-bbs2-0022" title="AyzenbergI , KatsaravaZ , SborowskiA , ChernyshM , OsipovaV , TabeevaG , et al. The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia2012;32(5):373-81. [DOI: 10.1177/0333102412438977 ]">Ayzenberg 2012</a>), and 9% for adults in China (<a href="./references#CD008541-bbs2-0071" title="YuS , LiuR , ZhaoG , YangX , QiaoX , FengJ , et al. The prevalence and burden of primary headaches in China: a population-based door-to-door survey. Headache2012;52(4):582-91. [DOI: 10.1111/j.1526-4610.2011.02061.x]">Yu 2012</a>). Migraine is more prevalent in women than in men (by a factor of two to three), and in the age range 30 to 50 years. </p> <p>The International Headache Society (IHS) classifies two major subtypes (<a href="./references#CD008541-bbs2-0042" title="Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia2013;33(9):629-808. [DOI: 10.1177/0333102413485658]">IHS 2013</a>). Migraine without aura is the most common subtype. It is characterised by attacks lasting 4 to 72 hours that are typically of moderate to severe pain intensity (PI), unilateral, pulsating, aggravated by normal physical activity, and associated with nausea with or without photophobia and phonophobia. Migraine with aura is characterised by reversible focal neurological symptoms that develop over a period of at least 5 minutes and last for less than 60 minutes, followed by headache with the features of migraine without aura. In some cases, the headache may lack migrainous features or be absent altogether (<a href="./references#CD008541-bbs2-0042" title="Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia2013;33(9):629-808. [DOI: 10.1177/0333102413485658]">IHS 2013</a>). </p> <p>A large prevalence study in the USA found that over half of migraineurs had severe impairment or required bed rest during attacks. Despite this high level of disability and a strong desire for successful treatment, only a proportion of migraine sufferers seek professional advice for the treatment of attacks. The majority were not taking any preventive medication, although one‐third met guideline criteria for offering or considering it. Nearly all (98%) migraineurs used acute treatments for attacks, with 49% using over‐the‐counter (OTC) medication only, 20% using prescription medication, and 29% using both. OTC medications included aspirin, other non‐steroidal anti‐inflammatory drugs (NSAIDs), paracetamol (acetaminophen), and paracetamol plus caffeine (<a href="./references#CD008541-bbs2-0024" title="BigalME , SerranoD , ReedM , LiptonRB . Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology2008;71(8):559-66. [DOI: 10.1212/01.wnl.0000323925.29520.e7]">Bigal 2008</a>; <a href="./references#CD008541-bbs2-0032" title="DiamondS , BigalME , SilbersteinS , LoderE , ReedM , LiptonRB . Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache2007;47(3):355-63. [DOI: 10.1111/j.1526-4610.2006.00631.x]">Diamond 2007</a>; <a href="./references#CD008541-bbs2-0051" title="LiptonRB , BigalME , DiamondM , FreitagF , ReedML . Migraine prevalence, disease burden, and the need for preventive therapy. Neurology2007;68(5):342-9. [DOI: 10.​1212/​01.​wnl.​0000252808.​97649.​21 ]">Lipton 2007</a>). Similar findings have been reported from other large studies in France and Germany (<a href="./references#CD008541-bbs2-0052" title="LucasC , GéraudG , ValadeD , ChautardMH , Lantéri-MinetM . Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population-based survey. Headache2006;46(5):715-25. [DOI: 10.1111/j.1526-4610.2006.00430.x]">Lucas 2006</a>; <a href="./references#CD008541-bbs2-0062" title="RadtkeA , NeuhauserH . Prevalence and burden of headache and migraine in Germany. Headache2009;49(1):79-89. [DOI: 10.1111/j.1526-4610.2008.01263.x]">Radtke 2009</a>). </p> <p>The significant impact of migraine with regard to pain, functional health, and well‐being is well documented (<a href="./references#CD008541-bbs2-0027" title="BuseD , ManackA , SerranoD , ReedM , VaronS , TurkelC , et al. Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study. Headache2012;52(1):3-17. [DOI: 10.1111/j.1526-4610.2011.02046.x]">Buse 2011</a>; <a href="./references#CD008541-bbs2-0048" title="LeonardiM , SteinerTJ , ScherAT , LiptonRB . The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). Journal of Headache and Pain2005;6(6):429-40. [DOI: 10.1007/s10194-005-0252-4]">Leonardi 2005</a>); it is ranked in the top 10 disorders for global years lived with disability (<a href="./references#CD008541-bbs2-0069" title="VosT , FlaxmanAD , NaghaviM , LozanoR , MichaudC , EzzatiM , et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet2012;380(9859):2163-96. [DOI: 1016/S0140-6736(12)61729-2]">Vos 2012</a>). A cross‐sectional survey of eight EU countries (representing 55% of the adult population) has estimated an annual direct and indirect cost of migraine per person of EUR 1222, and a total annual cost for the EU of EUR 111 billion for adults aged 18 to 65 years (<a href="./references#CD008541-bbs2-0049" title="LindeM , GustavssonA , StovnerLJ , SteinerTJ , BarréJ , KatsaravaZ , et al. The cost of headache disorders in Europe: the Eurolight project. European Journal of Neurology2012;19(5):703-11. [DOI: 10.1111/j.1468-1331.2011.03612.x]">Linde 2012</a>). Costs vary between countries, probably due to differences in available therapies and the way they are delivered, and structural differences in healthcare systems (<a href="./references#CD008541-bbs2-0025" title="BloudekLM , StokesM , BuseDC , WilcoxTK , LiptonRB , GoadsbyPJ , et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). Journal of Headache and Pain2012;13(5):361-78. [DOI: 10.1007/s10194-012-0460-7]">Bloudek 2012</a>). In the USA, the mean annual direct cost per person has been estimated at USD 1757 for episodic migraine and USD 7750 for chronic migraine (<a href="./references#CD008541-bbs2-0060" title="MunakataJ , HazardE , SerranoD , KlingmanD , RupnowMF , TierceJ , et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache2009;49(4):498-508. [DOI: 10.1111/j.1526-4610.2009.01369.x]">Munakata 2009</a>). Whatever the exact direct and indirect costs are for each country, it is clear that migraine presents a significant economic burden. Successful treatment of acute migraine attacks not only benefits patients by reducing their disability and improving health‐related quality of life, but also has the potential to reduce the need for healthcare resources and increase economic productivity. </p> </section> <section id="CD008541-sec-0011"> <h3 class="title" id="CD008541-sec-0011">Description of the intervention</h3> <p>The symptomatic treatment of migraine advanced significantly with the development of the triptan class of drugs, of which sumatriptan was the first. Sumatriptan is available as 50 mg and 100 mg oral tablets (maximum dose 300 mg in 24 hours) and also as a subcutaneous injection (6 mg dose, maximum 12 mg in 24 hours), intranasal spray (20 mg, maximum 40 mg in 24 hours), and rectal suppositories (12.5 mg and 25 mg). In most parts of the world it is available only by prescription, but in some countries it is available to the public without prescription. Naproxen is an NSAID first marketed in the mid‐1970s, with confirmed efficacy in acute (<a href="./references#CD008541-bbs2-0030" title="DerryC , DerryS , MooreRA , McQuayHJ . Single dose oral naproxen and naproxen sodium for acute postoperative pain in adults. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD004234.pub3]">Derry 2009</a>) and chronic (<a href="./references#CD008541-bbs2-0055" title="MooreRA , MooreOA , DerryS , PelosoPM , GammaitoniAR , WangH . Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases2010;69(2):374-9. [DOI: 10.1136/ard.2009.107805]">Moore 2010a</a>; <a href="./references#CD008541-bbs2-0056" title="MooreRA , SmugarSS , WangH , PelosoPM , GammaitoniA . Numbers-needed-to-treat analyses - do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials. Pain2010;151(3):592-7. [DOI: 10.1016/j.pain.2010.07.013]">Moore 2010b</a>) pain, and limited efficacy in migraine (<a href="./references#CD008541-bbs2-0047" title="LawS , DerryS , MooreRA . Naproxen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD009455]">Law 2013b</a>). It is a propionic acid derivative (of the same family as ibuprofen), with analgesic, anti‐inflammatory, and antipyretic properties. It has been widely used in treating arthritis, menstrual cramps, gout, sprains and strains, and a variety of acute pain conditions. Naproxen and its soluble sodium salt are commonly available as 250 mg and 500 mg tablets (275 mg and 550 mg of sodium salt). In many parts of the world it remains a prescription‐only drug, but in others such as the USA, UK, and most parts of Canada, it is available OTC in restricted doses. Both sumatriptan and naproxen are widely available generically and are marketed by a very large number of companies worldwide (http://www.drugs.com/international/sumatriptan.html and www.drugs.com/international/naproxen.html (accessed 31 March 2016)). </p> <p>A fixed‐dose combination tablet (trade name Trexima or Treximet; GlaxoSmithKline) containing sumatriptan 85 mg plus naproxen 500 mg is now available by prescription in the USA. It appears not to be available in Europe as of October 2015; we were unable to establish availability and licensing in other parts of the world. Compared with the individual components, the combination is expensive, and there was a very large increase in price in October 2014, to over USD 70 per tablet (<a href="./references#CD008541-bbs2-0036" title="http://www.goodrx.com/triptan-nsaid-combinations. http://www.goodrx.com/triptan-nsaid-combinations 2015 (accessed 19 November).">GoodRx 2015</a>; <a href="./references#CD008541-bbs2-0070" title="Sumatriptan/naproxen sodium. en.wikipedia.org/wiki/Sumatriptan/naproxen_sodium 2015 (accessed 19 November 2015).">Wikipedia 2015</a>). </p> <p>In order to establish whether sumatriptan plus naproxen is an effective analgesic combination at a specified dose in acute migraine attacks, it is necessary to study its effects in circumstances that permit detection of pain relief (PR). Such studies are carried out in individuals with established pain of moderate to severe intensity, using single doses of the interventions. Participants who experience an inadequate response with either placebo or active treatment are permitted to use rescue medication, and the intervention is considered to have failed in those individuals. In clinical practice, however, individuals would not normally wait until pain is of at least moderate severity, and may take a second dose of medication if the first dose does not provide adequate relief. Once analgesic efficacy is established in studies using single doses in established pain, further studies may investigate different treatment strategies and patient preferences. These are likely to include treating the migraine attack early while pain is mild, and using a low dose initially, with a second dose if response is inadequate. </p> </section> <section id="CD008541-sec-0012"> <h3 class="title" id="CD008541-sec-0012">How the intervention might work</h3> <p>The challenge in optimising therapy for acute migraine headaches is in providing broad coverage of the multiple pathogenic processes involved, which are thought to include several neural pathways becoming sequentially activated and sensitised as an attack develops (<a href="./references#CD008541-bbs2-0035" title="GoadsbyPJ , LiptonRB , FerrariMD . Migraine - current understanding and treatment. New England Journal of Medicine2002;346(4):257-70. [DOI: 10.1056/NEJMra010917]">Goadsby 2002</a>). </p> <p>Early in an attack, trigeminal nerve endings release vasoactive and inflammatory substances such as calcitonin gene‐related peptide and kinins. Calcitonin gene‐related peptide causes meningeal vasodilation, and kinins induce release of inflammatory prostaglandins. The resulting vascular and meningeal inflammation stimulates trigeminal nociceptors and activates central pathways via ascending pain pathways. Prolonged nociceptive input causes central foci to fire in a sustained continuous manner causing a symptomatic migraine attack. This is characteristic of the central sensitisation hypothesis (<a href="./references#CD008541-bbs2-0026" title="BursteinR . Deconstructing migraine headache into peripheral and central sensitisation. Pain2001;89(2-3):107-10. [DOI: 10.1016/S0304-3959(00)00478-4]">Burstein 2001</a>). </p> <p>Sumatriptan is a 5‐HT<sub>1</sub> agonist, selectively targeting the 5‐HT (serotonin) 1B and 1D receptors. It is suggested that it inhibits synaptic transmission from the periphery before central sensitisation occurs. Three putative mechanisms of therapeutic action are involved (<a href="./references#CD008541-bbs2-0034" title="FerrariMD , GoadsbyPJ , RoonKI , LiptonRB . Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia2002;22(8):633-58. [DOI: 10.1046/j.1468-2982.2002.00404.x ]">Ferrari 2002</a>): </p> <p> <ul id="CD008541-list-0001"> <li> <p>vasoconstriction of dilated meningeal blood vessels;</p> </li> <li> <p>inhibition of the release of vasoactive neuropeptides from perivascular trigeminal sensory neurons; </p> </li> <li> <p>reduction of pain signal transmission in the trigeminal dorsal horn.</p> </li> </ul> </p> <p>Non‐steroidal anti‐inflammatory drugs (NSAIDs) block the effect of cyclo‐oxygenase on arachidonic acid, which is responsible for the synthesis of prostaglandins. Prostaglandins mediate a variety of physiological functions including maintenance of the gastric mucosal barrier, regulation of renal blood flow, and regulation of endothelial tone, and they also play an important role in inflammatory and nociceptive processes. Naproxen is a reversible inhibitor of cyclo‐oxygenase. Unlike the triptans, which exert their effect peripherally, naproxen is thought to inhibit central sensitisation by attenuating meningeal inflammation and preventing central sensitisation arising from glial cells in the brain stem. In one study, naproxen suppressed central trigeminal neurons in an animal model of intracranial pain (<a href="./references#CD008541-bbs2-0044" title="JakubowskiM , LevyD ,  KainzV , Zhang X-C, KosarasB , BursteinR . Sensitization of central trigeminovascular neurons: blockade by intravenous naproxen infusion. Neuroscience2007;148(2):573-83. [DOI: 10.1016/j.neuroscience.2007.04.064]">Jakubowski 2007</a>). Because multiple mechanisms are involved in migraine, multi‐mechanism targeted therapy with sumatriptan plus naproxen may confer advantages over conventional monotherapy. </p> </section> <section id="CD008541-sec-0013"> <h3 class="title" id="CD008541-sec-0013">Why it is important to do this review</h3> <p>Other Cochrane reviews of treatments for acute migraine in adults have shown that oral sumatriptan had good efficacy (<a href="./references#CD008541-bbs2-0031" title="DerryCJ , DerryS , MooreRA . Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD008615.pub2]">Derry 2012</a>), and naproxen alone had limited efficacy (<a href="./references#CD008541-bbs2-0047" title="LawS , DerryS , MooreRA . Naproxen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD009455]">Law 2013b</a>). It is important to assess and analyse the data now available for combination therapy involving these two agents, particularly in the light of recent research showing that fixed‐dose combinations of analgesics generally provide enhanced analgesic efficacy in acute pain and migraine when compared with any single drug in the combination (<a href="./references#CD008541-bbs2-0057" title="MooreRA , DerryCJ , DerryS , StraubeS , McQuayHJ . A conservative method of testing whether combination analgesics produce additive or synergistic effects using evidence from acute pain and migraine. European Journal of Pain2012;16(4):585-91. [DOI: 10.1016/j.ejpain.2011.08.009]">Moore 2012</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008541-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008541-sec-0014"></div> <p>To determine the efficacy and tolerability of sumatriptan plus naproxen, administered together as separate tablets or taken as a fixed‐dose combination tablet, compared with placebo and other active interventions in the treatment of acute migraine attacks in adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008541-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008541-sec-0015"></div> <section id="CD008541-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008541-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised, double‐blind, placebo‐ or active‐controlled studies using sumatriptan plus naproxen to treat a migraine headache episode. Studies had to have a minimum of 10 participants per treatment arm and measure at least one of the outcomes specified below. We accepted studies reporting treatment of consecutive headache episodes if outcomes for the first, or each, episode were reported separately; first attack data were used preferentially. We accepted cross‐over studies if there was adequate washout (≥ 48 hours) between treatments. </p> </section> <section id="CD008541-sec-0018"> <h4 class="title">Types of participants</h4> <p>Studies enrolled adults (at least 18 years of age) with episodic migraine. We used the definition of migraine specified by the IHS (<a href="./references#CD008541-bbs2-0039" title="Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia1988;8 Suppl 7:1-96. [PMID: 3048700]">IHS 1988</a>; <a href="./references#CD008541-bbs2-0041" title="Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia2004;24 Suppl 1:9-160. [DOI: 10.1111/j.1468-2982.2003.00824.x]">IHS 2004</a>; <a href="./references#CD008541-bbs2-0042" title="Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia2013;33(9):629-808. [DOI: 10.1177/0333102413485658]">IHS 2013</a>), and excluded trials evaluating treatments for chronic migraine. We applied no other restrictions on migraine frequency, duration, or type (with or without aura). We accepted studies that included participants taking stable prophylactic therapy to reduce the frequency of migraine attacks. We provided details on any prophylactic therapy prescribed or allowed in the <a href="./references#CD008541-sec-0120" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD008541-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included studies in which self administered sumatriptan plus naproxen (as separate tablets administered together, or as a fixed‐dose combination tablet) was used to treat a migraine headache episode. We applied no restrictions on dose, dosing regimen (eg single dose versus optional second dose), or timing of the first dose in relation to headache intensity (eg taking the first dose when pain was of moderate to severe intensity versus when the pain was mild). </p> <p>A placebo comparator is essential to demonstrate that sumatriptan plus naproxen is effective in this condition. We considered active‐controlled trials without a placebo as secondary evidence. We excluded studies designed to demonstrate prophylactic efficacy in reducing the number or frequency of migraine headaches. </p> </section> <section id="CD008541-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD008541-sec-0021"> <h5 class="title">Primary outcomes</h5> <p>In selecting the main outcome measures for this review, we considered scientific rigour, availability of data, and patient preferences (<a href="./references#CD008541-bbs2-0050" title="LiptonRB , StewartWF . Acute migraine therapy: do doctors understand what patients with migraine want from therapy?Headache1999;39 Suppl 2:S20-6.">Lipton 1999</a>). Patients with acute migraine headaches have rated complete PR, no headache recurrence, rapid onset of PR, and no side effects as the four most important outcomes (<a href="./references#CD008541-bbs2-0050" title="LiptonRB , StewartWF . Acute migraine therapy: do doctors understand what patients with migraine want from therapy?Headache1999;39 Suppl 2:S20-6.">Lipton 1999</a>). </p> <p>In view of these patient preferences, and in line with the guidelines for controlled trials of drugs in migraine issued by the IHS (<a href="./references#CD008541-bbs2-0040" title="International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia2000;20(9):765-86. [DOI: 10.1046/j.1468-2982.2000.00117.x ]">IHS 2000</a>), the main outcomes that we considered were: </p> <p> <ul id="CD008541-list-0002"> <li> <p>pain‐free at two hours, without the use of rescue medication;</p> </li> <li> <p>reduction in headache pain ('headache relief') at two hours (pain reduced from moderate or severe to none or mild without the use of rescue medication). </p> </li> </ul> </p> <p>We also collected data for pain‐free and headache relief outcomes at one hour if reported.</p> </section> <section id="CD008541-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p>We considered the following secondary outcomes:</p> <p> <ul id="CD008541-list-0003"> <li> <p>sustained pain‐free during the 24 hours post dose (pain‐free within two hours, with no use of rescue medication or recurrence of moderate to severe pain within 24 hours); </p> </li> <li> <p>sustained headache relief during the 24 hours post dose (headache relief at two hours, sustained for 24 hours, with no use of rescue medication or a second dose of study medication); </p> </li> <li> <p>adverse events: participants with any adverse event during the 24 hours post dose; serious adverse events; adverse events leading to withdrawal. </p> </li> </ul> </p> </section> <section id="CD008541-sec-0023"> <h5 class="title">Other outcomes</h5> <p>We also collected data for other outcomes, where reported, including:</p> <p> <ul id="CD008541-list-0004"> <li> <p>use of rescue medication;</p> </li> <li> <p>relief of headache‐associated symptoms;</p> </li> <li> <p>relief of functional disability.</p> </li> </ul> </p> <p>PI or PR had to be measured by the participant (not the investigator or care provider). We accepted the following pain measures for the main efficacy outcomes: </p> <p> <ul id="CD008541-list-0005"> <li> <p>PI: 4‐point categorical scale, with wording equivalent to none, mild, moderate, and severe; or 100 mm visual analogue scale (VAS), where less than 30 mm was considered equivalent to mild or no pain and 30 mm or greater equivalent to moderate or severe pain (<a href="./references#CD008541-bbs2-0028" title="CollinsSL , MooreRA , McQuayHJ . The visual analogue pain intensity scale: what is moderate pain in millimetres?Pain1997;72(1-2):95-7. [DOI: 10.1016/S0304-3959(97)00005-5]">Collins 1997</a>); </p> </li> <li> <p>PR: 5‐point categorical scale, with wording equivalent to none, a little, some, a lot, and complete; or 100 mm VAS, where less than 30 mm was considered equivalent to none or a little, and 30 mm or greater equivalent to some, a lot, or complete. </p> </li> </ul> </p> <p>We considered only data obtained directly from the participant.</p> <p>Definitions of important terms, including all measured outcomes, are provided in <a href="./appendices#CD008541-sec-0099">Appendix 1</a>. </p> </section> </section> </section> <section id="CD008541-sec-0024"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008541-sec-0025"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases.</p> <p> <ul id="CD008541-list-0006"> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL), <i>The Cochrane Library,</i> (Issue 6 of 12, 2013 for the original review, and on 28 October 2015 via CRSO for this update). </p> </li> <li> <p>MEDLINE (via Ovid) (1946 to 28 October 2015).</p> </li> <li> <p>EMBASE (via Ovid) (1974 to 28 October 2015).</p> </li> </ul> </p> <p>See <a href="./appendices#CD008541-sec-0100">Appendix 2</a>, <a href="./appendices#CD008541-sec-0101">Appendix 3</a>, and <a href="./appendices#CD008541-sec-0102">Appendix 4</a> for the search strategies used for this update for CENTRAL (via CRSO), MEDLINE (via Ovid), and EMBASE (via Ovid), respectively. </p> <p>We applied no language restrictions.</p> </section> <section id="CD008541-sec-0026"> <h4 class="title">Searching other resources</h4> <p>We searched for additional studies in reference lists of retrieved studies and review articles, and in two clinical trials databases (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a> and <a href="http://www.gsk-clinicalstudyregister.com" target="_blank">www.gsk-clinicalstudyregister.com</a>). For the original review we contacted the manufacturer of the fixed‐dose combination agent (GlaxoSmithKline) for information about both published and unpublished data, but no additional studies were identified in their response. We did not search grey literature and abstracts. </p> </section> </section> <section id="CD008541-sec-0027"> <h3 class="title" id="CD008541-sec-0027">Data collection and analysis</h3> <section id="CD008541-sec-0028"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently carried out the searches and selected studies for inclusion. We viewed the titles and abstracts of all studies identified by electronic searches on screen and excluded any that clearly did not satisfy inclusion criteria. We read full copies of the remaining studies to identify those suitable for inclusion. Disagreements were settled by discussion with a third review author. </p> </section> <section id="CD008541-sec-0029"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted data from included studies using a standard data extraction form. We settled disagreements by discussion with a third review author. One review author entered data into Review Manager 5 (<a href="./references#CD008541-bbs2-0063" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). </p> </section> <section id="CD008541-sec-0030"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used the Oxford Quality Score as the basis for inclusion (<a href="./references#CD008541-bbs2-0043" title="JadadAR , MooreRA , CarrollD , JenkinsonC , ReynoldsDJM , GavaghanDJ , et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?Controlled Clinical Trials1996;17(1):1-12. [DOI: 10.1016/0197-2456(95)00134-4]">Jadad 1996</a>), limiting inclusion to studies that were randomised and double‐blind as a minimum. The scores for each study are reported in the <a href="./references#CD008541-sec-0120" title="">Characteristics of included studies</a> table. </p> <p>Two review authors independently assessed risk of bias for each study, using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Chapter 8.5, <a href="./references#CD008541-bbs2-0038" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>), and adapted from those used by the Cochrane Pregnancy and Childbirth Group, with any disagreements resolved by discussion. We assessed the following for each study. </p> <p> <ol id="CD008541-list-0007"> <li> <p>Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process: random number table; computer random number generator); unclear risk of bias (method used to generate sequence not clearly stated). We excluded studies using a non‐random process (odd or even date of birth; hospital or clinic record number). </p> </li> <li> <p>Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. We assessed the methods as: low risk of bias (telephone or central randomisation; consecutively numbered sealed opaque envelopes); unclear risk of bias (method not clearly stated). We excluded studies that did not conceal allocation (open list). </p> </li> <li> <p>Blinding of outcome assessment (checking for possible detection bias). We assessed the methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study states that it was blinded and describes the method used to achieve blinding: identical tablets; matched in appearance and smell); unclear risk of bias (study states that it was blinded but does not provide an adequate description of how it was achieved). We excluded studies that were not double‐blind. </p> </li> <li> <p>Incomplete outcome data (checking for possible attrition bias due to the amount, nature, and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk (&lt; 10% of participants provided no data without acceptable reason ‐ they were randomised but did not have a qualifying headache). We excluded studies with high data loss. </p> </li> <li> <p>Size of study (checking for possible biases confounded by small size). We assessed studies as being at low risk of bias (≥ 200 participants per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); high risk of bias (&lt; 50 participants per treatment arm). </p> </li> </ol> </p> </section> <section id="CD008541-sec-0031"> <h4 class="title">Measures of treatment effect</h4> <p>We used risk ratios (RR) to establish statistical difference. Numbers needed to treat for an additional beneficial outcome (NNT) and pooled percentages were used as absolute measures of benefit or harm. </p> <p>We used the following terms to describe adverse outcomes in terms of harm or prevention of harm: </p> <p> <ul id="CD008541-list-0008"> <li> <p>when significantly fewer adverse outcomes occurred with sumatriptan plus naproxen than with control (placebo or active), we use the term 'the number needed to treat to prevent one event' (NNTp); </p> </li> <li> <p>when significantly more adverse outcomes occur with sumatriptan plus naproxen compared with control (placebo or active), we use the term 'the number needed to harm or cause one event' (NNH). </p> </li> </ul> </p> </section> <section id="CD008541-sec-0032"> <h4 class="title">Unit of analysis issues</h4> <p>We planned to analyse data using the individual participant as the unit of analysis. In cross‐over studies we planned to use only first‐period data where possible, but where that was not provided, we used headache episode as the unit of analysis and treated the results as if they were parallel group results. We have commented on this. </p> </section> <section id="CD008541-sec-0033"> <h4 class="title">Dealing with missing data</h4> <p>The most likely source of missing data was in cross‐over studies. If there had been substantial missing data in any study, we planned sensitivity analyses to investigate their effects, but this was not an issue. </p> <p>For all outcomes we carried out analyses, as far as possible, on a modified intention‐to‐treat basis; that is, we included all participants who were randomised and received an intervention. Where sufficient information was reported, we re‐included missing data in the analyses we undertook. </p> </section> <section id="CD008541-sec-0034"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity of response rates using L'Abbé plots, a visual method for assessing differences in results of individual studies (<a href="./references#CD008541-bbs2-0046" title="L'AbbéKA , DetskyAS , O'RourkeK . Meta-analysis in clinical research. Annals of Internal Medicine1987;107(2):224-33. [DOI: 10.7326/0003-4819-107-2-224]">L'Abbé 1987</a>). Where data could be pooled, we reported the I² statistic. </p> </section> <section id="CD008541-sec-0035"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed publication bias by examining the number of participants in trials with zero effect (RR 1.0) needed for the point estimate of the NNT to increase beyond a clinically useful level (<a href="./references#CD008541-bbs2-0054" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA , editors(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-24. [ISBN: 978-0-931092-69-5]">Moore 2008</a>). In this case, we specified a clinically useful level as an NNT of 8 or greater for pain‐free at two hours, and NNT of 6 or greater for headache relief at two hours. </p> </section> <section id="CD008541-sec-0036"> <h4 class="title">Data synthesis</h4> <p>We analysed studies using a single dose of sumatriptan plus naproxen in established pain of at least moderate intensity separately from studies in which medication was taken before pain became well established, or in which a second dose of medication was permitted. </p> <p>We calculated effect sizes and combined data for analysis only for comparisons and outcomes where there were at least two studies and 200 participants (<a href="./references#CD008541-bbs2-0053" title="MooreRA , GavaghanD , TramerMR , CollinsSL , McQuayHJ . Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209-16. [DOI: 10.1016/S0304-3959(98)00140-7]">Moore 1998</a>). Risk ratio (relative benefit or harm) was calculated with 95% confidence intervals (CIs) using a fixed‐effect model (<a href="./references#CD008541-bbs2-0059" title="MorrisJA , GardnerMJ . Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates. In: Statistics with Confidence - Confidence Intervals and Statistical Guidelines. London: British Medical Journal, 1995:50-63. [ISBN: 0-7279-0222-0]">Morris 1995</a>). We calculated NNT, NNTp, and NNH with 95% CIs using the pooled number of events by the method of Cook and Sackett (<a href="./references#CD008541-bbs2-0029" title="CookRJ , SackettDL . The number needed to treat: a clinically useful measure of treatment effect. BMJ1995;310(6977):452-4. [DOI: 10.1136/bmj.310.6977.452]">Cook 1995</a>). We assumed a statistically significant difference from control when the 95% CI of the RR of benefit or harm did not include the number one. </p> <p>We used the z test to determine significant differences between NNT, NNTp, and NNH for different groups in subgroup and sensitivity analyses (<a href="./references#CD008541-bbs2-0067" title="TramèrMR , ReynoldsDJM , MooreRA , McQuayHJ . Impact of covert duplicate results on meta-analysis: a case study. BMJ1997;315(7109):635-40. [DOI: 10.1136/bmj.315.7109.635]">Tramèr 1997</a>). </p> <p>We described data from comparisons and outcomes with only one study or fewer than 200 participants in the text or summary tables, or both, where appropriate for information and comparison, but we did not analyse these data quantitatively. </p> <p>We have included a 'Summary of findings' table as set out in the PaPaS author guide (<a href="./references#CD008541-bbs2-0061" title="Cochrane Pain, Palliative and Supportive Care Group. PaPaS Author and Referee Guidance. http://papas.cochrane.org/papas-documents (accessed 19 November 2015).">PaPaS 2012</a>), and recommended in the Cochrane Handbook (Chapter 4.6.6, <a href="./references#CD008541-bbs2-0038" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>; <a href="./full#CD008541-tbl-0001">summary of findings Table 1</a>). The table includes outcomes of pain‐free at two hours, sustained pain‐free at 24 hours, and at least one adverse event for participants treating mild pain, and pain‐free or mild pain at 2 hours, sustained pain‐free at 24 hours, sustained headache relief at 24 hours, and at least one adverse event for participants treating moderate or severe pain. We combined results for all levels of baseline pain for participants with serious adverse events due to the small amount of data. We used the GRADE approach to assess the quality of evidence related to each of the key outcomes, and report our judgement on the quality of the evidence in the Summary of findings tables (chapter 12.2, <a href="./references#CD008541-bbs2-0038" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>; <a href="./appendices#CD008541-sec-0103">Appendix 5</a>). </p> </section> <section id="CD008541-sec-0037"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Issues for potential subgroup analysis were dose, timing of doses, route of administration, and multiple dosing strategies. A minimum of two studies and 200 participants had to be available for any subgroup analysis. </p> </section> <section id="CD008541-sec-0038"> <h4 class="title">Sensitivity analysis</h4> <p>We planned a sensitivity analysis for menstrual migraine versus non‐menstrual migraine. A minimum of two studies and 200 participants had to be available for any sensitivity analysis. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008541-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008541-sec-0039"></div> <section id="CD008541-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD008541-sec-0041"> <h4 class="title">Results of the search</h4> <p>For the earlier review we identified 18 potentially relevant studies, of which we included 12 and excluded six. For this update we identified a further six potentially relevant studies. One of these studies satisfied our inclusion criteria (<a href="./references#CD008541-bbs2-0003" title="CalhounAH , FordS . Double-blind, placebo-controlled, crossover study of early-intervention with sumatriptan 85/naproxen sodium 500 in (truly) episodic migraine: what's neck pain got to do with it?Postgraduate Medicine2014;126(2):86-90. [DOI: 10.3810/pgm.2014.03.2743]">Calhoun 2014</a>), two were secondary analyses of studies that were already included (Landy 2014 from <a href="./references#CD008541-bbs2-0004" title="LandySH , CadyRK , NelsenA , WhiteJ , RunkenMC . Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination. Headache2014;54(4):640-54. [DOI: 10.1111/head.12214]LiptonRB , DodickDW , AdelmanJU , KanieckiRG , LenerSE , WhiteJD , et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia2009;29(8):826-36. [DOI: 10.1111/j.1468-2982.2008.01806.x]">Lipton 2009 Study 1</a> and <a href="./references#CD008541-bbs2-0005" title="LandySH , CadyRK , NelsenA , WhiteJ , RunkenMC . Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination. Headache2014;54(4):640-54. [DOI: 10.1111/head.12214]LiptonRB , DodickDW , AdelmanJU , KanieckiRG , LenerSE , WhiteJD , et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia2009;29(8):826-36. [DOI: 10.1111/j.1468-2982.2008.01806.x]">Lipton 2009 Study 2</a>, Martin 2014 from <a href="./references#CD008541-bbs2-0006" title="CadyRK , DiamondML , DiamondMP , BallardJE , LenerME , DornerDP , et al. Sumatriptan - naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache2011;51(5):664-73. [DOI: 10.1111/j.1526-4610.2011.01894.x]MannixLK , MartinVT , CadyRK , DiamondML , LenerSE , WhiteJD , et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Journal of Obstetrics and Gynecology2009;114(1):106-13. [DOI: 10.1097/AOG.0b013e3181a98e4d]MartinVT , BallardJ , DiamondMP , MannixLK , DerosierFJ , LenerSE , et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Journal of Women's Health2014;23(5):389-96. [DOI: 10.1089/jwh.2013.4577]">Mannix 2009 Study 1</a> and <a href="./references#CD008541-bbs2-0007" title="CadyRK , DiamondML , DiamondMP , BallardJE , LenerME , DornerDP , et al. Sumatriptan - naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache2011;51(5):664-73. [DOI: 10.1111/j.1526-4610.2011.01894.x]MannixLK , MartinVT , CadyRK , DiamondML , LenerSE , WhiteJD , et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Journal of Obstetrics and Gynecology2009;114(1):106-13. [DOI: 10.1097/AOG.0b013e3181a98e4d]MartinVT , BallardJ , DiamondMP , MannixLK , DerosierFJ , LenerSE , et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Journal of Women's Health2014;23(5):389-96. [DOI: 10.1089/jwh.2013.4577]">Mannix 2009 Study 2</a>), one was a full publication of an already excluded study previously identified in a clinical trial registry (Silberstien 2014 from <a href="./references#CD008541-bbs2-0019" title="Glazo Smith Kline study register. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and tolerability of TREXIMET (sumatriptan 85mg and naproxen sodium 500mg) for a single moderate or severe headache in adults diagnosed with probable migraine without aura. www.clinicaltrials.gov/ct2/show/NCT00387881 (accessed 23 September 2013). SilbersteinS , McDonaldSA , GoldsteinJ , AuroraS , LenerSE , WhiteJ , et al. Sumatriptan/naproxen sodium for the acute treatment of probable migraine without aura: a randomized study. Cephalalgia2014;34(4):268-79. [DOI: 10.1177/0333102413508242]">TRX107563</a>), and we excluded two studies (<a href="./references#CD008541-bbs2-0014" title="CadyR , O'CarrollP , DexterK , FreitagF , ShadeCL . SumaRT/nap vs naproxen sodium in treatment and disease modification of migraine: a pilot study. Headache2014;54(1):67-79. [DOI: 10.1111/head.12211]">Cady 2014</a>; <a href="./references#CD008541-bbs2-0015" title="EdwardsKR , RosenthalBL , FarmerKU , CadyRK , BrowningR . Evaluation of sumatriptan-naproxen in the treatment of acute migraine: a placebo-controlled, double-blind, cross-over study assessing cognitive function. Headache2013;53(4):656-64. [DOI: 10.1111/head.12052]">Edwards 2013</a>). </p> <p><a href="#CD008541-fig-0001">Figure 1</a> shows the results of the updated searches. </p> <div class="figure" id="CD008541-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD008541-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD008541-sec-0042"> <h4 class="title">Included studies</h4> <p>Thirteen studies (with data reported in eight primary publications) satisfied all inclusion criteria and are included in this review. Seven studies used a parallel group design (<a href="./references#CD008541-bbs2-0001" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 1</a>; <a href="./references#CD008541-bbs2-0002" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 2</a>; <a href="./references#CD008541-bbs2-0006" title="CadyRK , DiamondML , DiamondMP , BallardJE , LenerME , DornerDP , et al. Sumatriptan - naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache2011;51(5):664-73. [DOI: 10.1111/j.1526-4610.2011.01894.x]MannixLK , MartinVT , CadyRK , DiamondML , LenerSE , WhiteJD , et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Journal of Obstetrics and Gynecology2009;114(1):106-13. [DOI: 10.1097/AOG.0b013e3181a98e4d]MartinVT , BallardJ , DiamondMP , MannixLK , DerosierFJ , LenerSE , et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Journal of Women's Health2014;23(5):389-96. [DOI: 10.1089/jwh.2013.4577]">Mannix 2009 Study 1</a>; <a href="./references#CD008541-bbs2-0007" title="CadyRK , DiamondML , DiamondMP , BallardJE , LenerME , DornerDP , et al. Sumatriptan - naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache2011;51(5):664-73. [DOI: 10.1111/j.1526-4610.2011.01894.x]MannixLK , MartinVT , CadyRK , DiamondML , LenerSE , WhiteJD , et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Journal of Obstetrics and Gynecology2009;114(1):106-13. [DOI: 10.1097/AOG.0b013e3181a98e4d]MartinVT , BallardJ , DiamondMP , MannixLK , DerosierFJ , LenerSE , et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Journal of Women's Health2014;23(5):389-96. [DOI: 10.1089/jwh.2013.4577]">Mannix 2009 Study 2</a>; <a href="./references#CD008541-bbs2-0010" title="SilbersteinSD , MannixLK , GoldsteinJ , CouchJR , ByrdSC , AmesMH , et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology2008;71(2):114-21. [DOI: 10.1212/01.wnl.0000316800.22949.20]TaylorFR , HeiringJO , MessinaE , Braverman-PanzaJ , AmesMH , ByrdSC , et al. Sumatriptan/naproxen sodium as early intervention for migraine: effects on functional ability, productivity, and satisfaction in 2 randomized controlled trials. Journal of Clinical Outcomes Management2007;14(4):195-204. ">Silberstein 2008 Study 1</a>; <a href="./references#CD008541-bbs2-0011" title="SilbersteinSD , MannixLK , GoldsteinJ , CouchJR , ByrdSC , AmesMH , et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology2008;71(2):114-21. [DOI: 10.1212/01.wnl.0000316800.22949.20]TaylorFR , HeiringJO , MessinaE , Braverman-PanzaJ , AmesMH , ByrdSC , et al. Sumatriptan/naproxen sodium as early intervention for migraine: effects on functional ability, productivity, and satisfaction in 2 randomized controlled trials. Journal of Clinical Outcomes Management2007;14(4):195-204. ">Silberstein 2008 Study 2</a>; <a href="./references#CD008541-bbs2-0012" title="SmithTR , SunshineA , StarkSR , LittlefieldDE , SpruillSE , AlexanderWJ . Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache2005;45(8):983-91. [DOI: 10.1111/j.1526-4610.2005.05178.x]">Smith 2005</a>), and six studies were cross‐over in design (<a href="./references#CD008541-bbs2-0003" title="CalhounAH , FordS . Double-blind, placebo-controlled, crossover study of early-intervention with sumatriptan 85/naproxen sodium 500 in (truly) episodic migraine: what's neck pain got to do with it?Postgraduate Medicine2014;126(2):86-90. [DOI: 10.3810/pgm.2014.03.2743]">Calhoun 2014</a>; <a href="./references#CD008541-bbs2-0004" title="LandySH , CadyRK , NelsenA , WhiteJ , RunkenMC . Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination. Headache2014;54(4):640-54. [DOI: 10.1111/head.12214]LiptonRB , DodickDW , AdelmanJU , KanieckiRG , LenerSE , WhiteJD , et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia2009;29(8):826-36. [DOI: 10.1111/j.1468-2982.2008.01806.x]">Lipton 2009 Study 1</a>; <a href="./references#CD008541-bbs2-0005" title="LandySH , CadyRK , NelsenA , WhiteJ , RunkenMC . Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination. Headache2014;54(4):640-54. [DOI: 10.1111/head.12214]LiptonRB , DodickDW , AdelmanJU , KanieckiRG , LenerSE , WhiteJD , et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia2009;29(8):826-36. [DOI: 10.1111/j.1468-2982.2008.01806.x]">Lipton 2009 Study 2</a>; <a href="./references#CD008541-bbs2-0008" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 1;</a><a href="./references#CD008541-bbs2-0009" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 2</a>; <a href="./references#CD008541-bbs2-0013" title="A randomized, double-blind, double-dummy, placebo-controlled, crossover study to evaluate the efficacy of TREXIMET (sumatriptan + naproxen sodium) versus Butalbital-Containing Combination Medications (BCM) for the acute treatment of migraine when administered during the moderate-severe pain phase of the migraine (pooled data), 2010. download.gsk-clinicalstudyregister.com/files/21144.pdf (accessed 23 September 2013). DerosierF , SheftellF , SilbersteinS , CadyR , RuoffG , KrishenA , et al. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache2012;52(4):530-43. [DOI: 10.1111/j.1526-4610.2011.02039.x]">TRX109011/13</a>). <a href="./references#CD008541-bbs2-0013" title="A randomized, double-blind, double-dummy, placebo-controlled, crossover study to evaluate the efficacy of TREXIMET (sumatriptan + naproxen sodium) versus Butalbital-Containing Combination Medications (BCM) for the acute treatment of migraine when administered during the moderate-severe pain phase of the migraine (pooled data), 2010. download.gsk-clinicalstudyregister.com/files/21144.pdf (accessed 23 September 2013). DerosierF , SheftellF , SilbersteinS , CadyR , RuoffG , KrishenA , et al. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache2012;52(4):530-43. [DOI: 10.1111/j.1526-4610.2011.02039.x]">TRX109011/13</a> was available only as a clinical trial summary with results at the time that initial data extraction was carried out, but has subsequently been published in a peer‐reviewed journal (Derosier 2012). For two of the cross‐over studies treating more than one episode with the same medication, we used data from the first period (<a href="./references#CD008541-bbs2-0004" title="LandySH , CadyRK , NelsenA , WhiteJ , RunkenMC . Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination. Headache2014;54(4):640-54. [DOI: 10.1111/head.12214]LiptonRB , DodickDW , AdelmanJU , KanieckiRG , LenerSE , WhiteJD , et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia2009;29(8):826-36. [DOI: 10.1111/j.1468-2982.2008.01806.x]">Lipton 2009 Study 1</a>; <a href="./references#CD008541-bbs2-0005" title="LandySH , CadyRK , NelsenA , WhiteJ , RunkenMC . Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination. Headache2014;54(4):640-54. [DOI: 10.1111/head.12214]LiptonRB , DodickDW , AdelmanJU , KanieckiRG , LenerSE , WhiteJD , et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia2009;29(8):826-36. [DOI: 10.1111/j.1468-2982.2008.01806.x]">Lipton 2009 Study 2</a>). The third cross‐over study treating more than one episode with the same medication reported only a percentage response for active and placebo treatments, and it was not clear what denominator had been used, so we were unable to use these data in the analysis (<a href="./references#CD008541-bbs2-0003" title="CalhounAH , FordS . Double-blind, placebo-controlled, crossover study of early-intervention with sumatriptan 85/naproxen sodium 500 in (truly) episodic migraine: what's neck pain got to do with it?Postgraduate Medicine2014;126(2):86-90. [DOI: 10.3810/pgm.2014.03.2743]">Calhoun 2014</a>). First period only data were not reported for the other three cross‐over studies (<a href="./references#CD008541-bbs2-0008" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 1</a>; <a href="./references#CD008541-bbs2-0009" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 2</a>; <a href="./references#CD008541-bbs2-0013" title="A randomized, double-blind, double-dummy, placebo-controlled, crossover study to evaluate the efficacy of TREXIMET (sumatriptan + naproxen sodium) versus Butalbital-Containing Combination Medications (BCM) for the acute treatment of migraine when administered during the moderate-severe pain phase of the migraine (pooled data), 2010. download.gsk-clinicalstudyregister.com/files/21144.pdf (accessed 23 September 2013). DerosierF , SheftellF , SilbersteinS , CadyR , RuoffG , KrishenA , et al. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache2012;52(4):530-43. [DOI: 10.1111/j.1526-4610.2011.02039.x]">TRX109011/13</a>), so we used combined data for analyses, with a post‐hoc sensitivity analysis in addition to those sensitivity analyses outlined in the protocol. In nine studies, medication was to be taken early in the attack, while PI was still mild (<a href="./references#CD008541-bbs2-0003" title="CalhounAH , FordS . Double-blind, placebo-controlled, crossover study of early-intervention with sumatriptan 85/naproxen sodium 500 in (truly) episodic migraine: what's neck pain got to do with it?Postgraduate Medicine2014;126(2):86-90. [DOI: 10.3810/pgm.2014.03.2743]">Calhoun 2014</a>; <a href="./references#CD008541-bbs2-0004" title="LandySH , CadyRK , NelsenA , WhiteJ , RunkenMC . Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination. Headache2014;54(4):640-54. [DOI: 10.1111/head.12214]LiptonRB , DodickDW , AdelmanJU , KanieckiRG , LenerSE , WhiteJD , et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia2009;29(8):826-36. [DOI: 10.1111/j.1468-2982.2008.01806.x]">Lipton 2009 Study 1;</a><a href="./references#CD008541-bbs2-0005" title="LandySH , CadyRK , NelsenA , WhiteJ , RunkenMC . Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination. Headache2014;54(4):640-54. [DOI: 10.1111/head.12214]LiptonRB , DodickDW , AdelmanJU , KanieckiRG , LenerSE , WhiteJD , et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia2009;29(8):826-36. [DOI: 10.1111/j.1468-2982.2008.01806.x]">Lipton 2009 Study 2</a>; <a href="./references#CD008541-bbs2-0006" title="CadyRK , DiamondML , DiamondMP , BallardJE , LenerME , DornerDP , et al. Sumatriptan - naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache2011;51(5):664-73. [DOI: 10.1111/j.1526-4610.2011.01894.x]MannixLK , MartinVT , CadyRK , DiamondML , LenerSE , WhiteJD , et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Journal of Obstetrics and Gynecology2009;114(1):106-13. [DOI: 10.1097/AOG.0b013e3181a98e4d]MartinVT , BallardJ , DiamondMP , MannixLK , DerosierFJ , LenerSE , et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Journal of Women's Health2014;23(5):389-96. [DOI: 10.1089/jwh.2013.4577]">Mannix 2009 Study 1;</a><a href="./references#CD008541-bbs2-0007" title="CadyRK , DiamondML , DiamondMP , BallardJE , LenerME , DornerDP , et al. Sumatriptan - naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache2011;51(5):664-73. [DOI: 10.1111/j.1526-4610.2011.01894.x]MannixLK , MartinVT , CadyRK , DiamondML , LenerSE , WhiteJD , et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Journal of Obstetrics and Gynecology2009;114(1):106-13. [DOI: 10.1097/AOG.0b013e3181a98e4d]MartinVT , BallardJ , DiamondMP , MannixLK , DerosierFJ , LenerSE , et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Journal of Women's Health2014;23(5):389-96. [DOI: 10.1089/jwh.2013.4577]">Mannix 2009 Study 2</a>; <a href="./references#CD008541-bbs2-0008" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 1</a>; <a href="./references#CD008541-bbs2-0009" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 2</a>; <a href="./references#CD008541-bbs2-0010" title="SilbersteinSD , MannixLK , GoldsteinJ , CouchJR , ByrdSC , AmesMH , et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology2008;71(2):114-21. [DOI: 10.1212/01.wnl.0000316800.22949.20]TaylorFR , HeiringJO , MessinaE , Braverman-PanzaJ , AmesMH , ByrdSC , et al. Sumatriptan/naproxen sodium as early intervention for migraine: effects on functional ability, productivity, and satisfaction in 2 randomized controlled trials. Journal of Clinical Outcomes Management2007;14(4):195-204. ">Silberstein 2008 Study 1;</a><a href="./references#CD008541-bbs2-0011" title="SilbersteinSD , MannixLK , GoldsteinJ , CouchJR , ByrdSC , AmesMH , et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology2008;71(2):114-21. [DOI: 10.1212/01.wnl.0000316800.22949.20]TaylorFR , HeiringJO , MessinaE , Braverman-PanzaJ , AmesMH , ByrdSC , et al. Sumatriptan/naproxen sodium as early intervention for migraine: effects on functional ability, productivity, and satisfaction in 2 randomized controlled trials. Journal of Clinical Outcomes Management2007;14(4):195-204. ">Silberstein 2008 Study 2</a>), and in the remaining four studies when it was moderate or severe (<a href="./references#CD008541-bbs2-0001" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 1;</a><a href="./references#CD008541-bbs2-0002" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 2</a>; <a href="./references#CD008541-bbs2-0012" title="SmithTR , SunshineA , StarkSR , LittlefieldDE , SpruillSE , AlexanderWJ . Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache2005;45(8):983-91. [DOI: 10.1111/j.1526-4610.2005.05178.x]">Smith 2005</a>; <a href="./references#CD008541-bbs2-0013" title="A randomized, double-blind, double-dummy, placebo-controlled, crossover study to evaluate the efficacy of TREXIMET (sumatriptan + naproxen sodium) versus Butalbital-Containing Combination Medications (BCM) for the acute treatment of migraine when administered during the moderate-severe pain phase of the migraine (pooled data), 2010. download.gsk-clinicalstudyregister.com/files/21144.pdf (accessed 23 September 2013). DerosierF , SheftellF , SilbersteinS , CadyR , RuoffG , KrishenA , et al. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache2012;52(4):530-43. [DOI: 10.1111/j.1526-4610.2011.02039.x]">TRX109011/13</a>). No studies employed multiple dosing strategies for a single attack. </p> <p>Two further publications reported data on functional disability that were not reported in the primary publications; Landy 2007 for <a href="./references#CD008541-bbs2-0001" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 1</a> and <a href="./references#CD008541-bbs2-0002" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 2</a> and Taylor 2007 for <a href="./references#CD008541-bbs2-0010" title="SilbersteinSD , MannixLK , GoldsteinJ , CouchJR , ByrdSC , AmesMH , et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology2008;71(2):114-21. [DOI: 10.1212/01.wnl.0000316800.22949.20]TaylorFR , HeiringJO , MessinaE , Braverman-PanzaJ , AmesMH , ByrdSC , et al. Sumatriptan/naproxen sodium as early intervention for migraine: effects on functional ability, productivity, and satisfaction in 2 randomized controlled trials. Journal of Clinical Outcomes Management2007;14(4):195-204. ">Silberstein 2008 Study 1</a> and <a href="./references#CD008541-bbs2-0011" title="SilbersteinSD , MannixLK , GoldsteinJ , CouchJR , ByrdSC , AmesMH , et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology2008;71(2):114-21. [DOI: 10.1212/01.wnl.0000316800.22949.20]TaylorFR , HeiringJO , MessinaE , Braverman-PanzaJ , AmesMH , ByrdSC , et al. Sumatriptan/naproxen sodium as early intervention for migraine: effects on functional ability, productivity, and satisfaction in 2 randomized controlled trials. Journal of Clinical Outcomes Management2007;14(4):195-204. ">Silberstein 2008 Study 2</a>. Other publications reported satisfaction, productivity, and functional disability outcomes for participants in <a href="./references#CD008541-bbs2-0006" title="CadyRK , DiamondML , DiamondMP , BallardJE , LenerME , DornerDP , et al. Sumatriptan - naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache2011;51(5):664-73. [DOI: 10.1111/j.1526-4610.2011.01894.x]MannixLK , MartinVT , CadyRK , DiamondML , LenerSE , WhiteJD , et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Journal of Obstetrics and Gynecology2009;114(1):106-13. [DOI: 10.1097/AOG.0b013e3181a98e4d]MartinVT , BallardJ , DiamondMP , MannixLK , DerosierFJ , LenerSE , et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Journal of Women's Health2014;23(5):389-96. [DOI: 10.1089/jwh.2013.4577]">Mannix 2009 Study 1</a> and <a href="./references#CD008541-bbs2-0007" title="CadyRK , DiamondML , DiamondMP , BallardJE , LenerME , DornerDP , et al. Sumatriptan - naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache2011;51(5):664-73. [DOI: 10.1111/j.1526-4610.2011.01894.x]MannixLK , MartinVT , CadyRK , DiamondML , LenerSE , WhiteJD , et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Journal of Obstetrics and Gynecology2009;114(1):106-13. [DOI: 10.1097/AOG.0b013e3181a98e4d]MartinVT , BallardJ , DiamondMP , MannixLK , DerosierFJ , LenerSE , et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Journal of Women's Health2014;23(5):389-96. [DOI: 10.1089/jwh.2013.4577]">Mannix 2009 Study 2</a> (Cady 2011), and in <a href="./references#CD008541-bbs2-0004" title="LandySH , CadyRK , NelsenA , WhiteJ , RunkenMC . Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination. Headache2014;54(4):640-54. [DOI: 10.1111/head.12214]LiptonRB , DodickDW , AdelmanJU , KanieckiRG , LenerSE , WhiteJD , et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia2009;29(8):826-36. [DOI: 10.1111/j.1468-2982.2008.01806.x]">Lipton 2009 Study 1</a> and <a href="./references#CD008541-bbs2-0005" title="LandySH , CadyRK , NelsenA , WhiteJ , RunkenMC . Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination. Headache2014;54(4):640-54. [DOI: 10.1111/head.12214]LiptonRB , DodickDW , AdelmanJU , KanieckiRG , LenerSE , WhiteJD , et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia2009;29(8):826-36. [DOI: 10.1111/j.1468-2982.2008.01806.x]">Lipton 2009 Study 2</a> (Landy 2014). Martin 2014 reported a pooled analysis of relief of menstrual symptoms in <a href="./references#CD008541-bbs2-0006" title="CadyRK , DiamondML , DiamondMP , BallardJE , LenerME , DornerDP , et al. Sumatriptan - naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache2011;51(5):664-73. [DOI: 10.1111/j.1526-4610.2011.01894.x]MannixLK , MartinVT , CadyRK , DiamondML , LenerSE , WhiteJD , et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Journal of Obstetrics and Gynecology2009;114(1):106-13. [DOI: 10.1097/AOG.0b013e3181a98e4d]MartinVT , BallardJ , DiamondMP , MannixLK , DerosierFJ , LenerSE , et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Journal of Women's Health2014;23(5):389-96. [DOI: 10.1089/jwh.2013.4577]">Mannix 2009 Study 1</a> and <a href="./references#CD008541-bbs2-0007" title="CadyRK , DiamondML , DiamondMP , BallardJE , LenerME , DornerDP , et al. Sumatriptan - naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache2011;51(5):664-73. [DOI: 10.1111/j.1526-4610.2011.01894.x]MannixLK , MartinVT , CadyRK , DiamondML , LenerSE , WhiteJD , et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Journal of Obstetrics and Gynecology2009;114(1):106-13. [DOI: 10.1097/AOG.0b013e3181a98e4d]MartinVT , BallardJ , DiamondMP , MannixLK , DerosierFJ , LenerSE , et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Journal of Women's Health2014;23(5):389-96. [DOI: 10.1089/jwh.2013.4577]">Mannix 2009 Study 2</a>, but this was not of relevance to this review. </p> <p>All studies were multicentre except <a href="./references#CD008541-bbs2-0003" title="CalhounAH , FordS . Double-blind, placebo-controlled, crossover study of early-intervention with sumatriptan 85/naproxen sodium 500 in (truly) episodic migraine: what's neck pain got to do with it?Postgraduate Medicine2014;126(2):86-90. [DOI: 10.3810/pgm.2014.03.2743]">Calhoun 2014</a>, and all diagnosed migraine (with or without aura) according to IHS criteria. People with frequent migraine headaches (more than six or eight attacks per month) were excluded. In <a href="./references#CD008541-bbs2-0003" title="CalhounAH , FordS . Double-blind, placebo-controlled, crossover study of early-intervention with sumatriptan 85/naproxen sodium 500 in (truly) episodic migraine: what's neck pain got to do with it?Postgraduate Medicine2014;126(2):86-90. [DOI: 10.3810/pgm.2014.03.2743]">Calhoun 2014</a>, people with more than eight attacks per month or more than 15 days per month with either headache or neck pain were excluded. Most studies required that participants had previously tolerated treatment with a triptan or had no contraindications, or both, but <a href="./references#CD008541-bbs2-0008" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 1</a> and <a href="./references#CD008541-bbs2-0009" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 2</a> included participants who had specifically been previous poor responders to triptans with a short half‐life, including sumatriptan, and <a href="./references#CD008541-bbs2-0013" title="A randomized, double-blind, double-dummy, placebo-controlled, crossover study to evaluate the efficacy of TREXIMET (sumatriptan + naproxen sodium) versus Butalbital-Containing Combination Medications (BCM) for the acute treatment of migraine when administered during the moderate-severe pain phase of the migraine (pooled data), 2010. download.gsk-clinicalstudyregister.com/files/21144.pdf (accessed 23 September 2013). DerosierF , SheftellF , SilbersteinS , CadyR , RuoffG , KrishenA , et al. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache2012;52(4):530-43. [DOI: 10.1111/j.1526-4610.2011.02039.x]">TRX109011/13</a> required that participants had previous experience using barbiturate‐containing medicines. In all studies, participants self treated their headaches at home. Two studies included only participants with menstrual migraine (<a href="./references#CD008541-bbs2-0006" title="CadyRK , DiamondML , DiamondMP , BallardJE , LenerME , DornerDP , et al. Sumatriptan - naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache2011;51(5):664-73. [DOI: 10.1111/j.1526-4610.2011.01894.x]MannixLK , MartinVT , CadyRK , DiamondML , LenerSE , WhiteJD , et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Journal of Obstetrics and Gynecology2009;114(1):106-13. [DOI: 10.1097/AOG.0b013e3181a98e4d]MartinVT , BallardJ , DiamondMP , MannixLK , DerosierFJ , LenerSE , et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Journal of Women's Health2014;23(5):389-96. [DOI: 10.1089/jwh.2013.4577]">Mannix 2009 Study 1;</a><a href="./references#CD008541-bbs2-0007" title="CadyRK , DiamondML , DiamondMP , BallardJE , LenerME , DornerDP , et al. Sumatriptan - naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache2011;51(5):664-73. [DOI: 10.1111/j.1526-4610.2011.01894.x]MannixLK , MartinVT , CadyRK , DiamondML , LenerSE , WhiteJD , et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Journal of Obstetrics and Gynecology2009;114(1):106-13. [DOI: 10.1097/AOG.0b013e3181a98e4d]MartinVT , BallardJ , DiamondMP , MannixLK , DerosierFJ , LenerSE , et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Journal of Women's Health2014;23(5):389-96. [DOI: 10.1089/jwh.2013.4577]">Mannix 2009 Study 2</a>). Overall, the mean age of participants ranged from 36 to 43 years, and between 85% and 100% were female. Generally, participants were eligible for inclusion if they were using stable prophylactic medication provided it was not a triptan, methysergide, or ergot derivative. Cross‐over studies where we used combined data across treatment periods (<a href="./references#CD008541-bbs2-0008" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 1</a>; <a href="./references#CD008541-bbs2-0009" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 2</a>; <a href="./references#CD008541-bbs2-0013" title="A randomized, double-blind, double-dummy, placebo-controlled, crossover study to evaluate the efficacy of TREXIMET (sumatriptan + naproxen sodium) versus Butalbital-Containing Combination Medications (BCM) for the acute treatment of migraine when administered during the moderate-severe pain phase of the migraine (pooled data), 2010. download.gsk-clinicalstudyregister.com/files/21144.pdf (accessed 23 September 2013). DerosierF , SheftellF , SilbersteinS , CadyR , RuoffG , KrishenA , et al. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache2012;52(4):530-43. [DOI: 10.1111/j.1526-4610.2011.02039.x]">TRX109011/13</a>) had adequate washout periods between treatments of at least one week. The washout period was not specified in two other cross‐over studies (<a href="./references#CD008541-bbs2-0004" title="LandySH , CadyRK , NelsenA , WhiteJ , RunkenMC . Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination. Headache2014;54(4):640-54. [DOI: 10.1111/head.12214]LiptonRB , DodickDW , AdelmanJU , KanieckiRG , LenerSE , WhiteJD , et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia2009;29(8):826-36. [DOI: 10.1111/j.1468-2982.2008.01806.x]">Lipton 2009 Study 1</a>; <a href="./references#CD008541-bbs2-0005" title="LandySH , CadyRK , NelsenA , WhiteJ , RunkenMC . Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination. Headache2014;54(4):640-54. [DOI: 10.1111/head.12214]LiptonRB , DodickDW , AdelmanJU , KanieckiRG , LenerSE , WhiteJD , et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia2009;29(8):826-36. [DOI: 10.1111/j.1468-2982.2008.01806.x]">Lipton 2009 Study 2</a>); for these, first period only data were available and were used for analyses. <a href="./references#CD008541-bbs2-0003" title="CalhounAH , FordS . Double-blind, placebo-controlled, crossover study of early-intervention with sumatriptan 85/naproxen sodium 500 in (truly) episodic migraine: what's neck pain got to do with it?Postgraduate Medicine2014;126(2):86-90. [DOI: 10.3810/pgm.2014.03.2743]">Calhoun 2014</a> specified only that the preceding day was completely free of both headache and neck pain. </p> <p>Twelve studies gave sumatriptan 85 mg plus naproxen 500 mg formulated as a combination tablet, while <a href="./references#CD008541-bbs2-0012" title="SmithTR , SunshineA , StarkSR , LittlefieldDE , SpruillSE , AlexanderWJ . Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache2005;45(8):983-91. [DOI: 10.1111/j.1526-4610.2005.05178.x]">Smith 2005</a> gave sumatriptan 50 mg plus naproxen 500 mg as separate tablets taken together. All studies compared sumatriptan plus naproxen versus placebo, and three studies included treatment arms using sumatriptan 85 mg (<a href="./references#CD008541-bbs2-0001" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 1;</a><a href="./references#CD008541-bbs2-0002" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 2</a>) or 50 mg (<a href="./references#CD008541-bbs2-0012" title="SmithTR , SunshineA , StarkSR , LittlefieldDE , SpruillSE , AlexanderWJ . Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache2005;45(8):983-91. [DOI: 10.1111/j.1526-4610.2005.05178.x]">Smith 2005</a>) and naproxen 500 mg alone. One study compared the combination with placebo and a butalbital‐containing active comparator (<a href="./references#CD008541-bbs2-0013" title="A randomized, double-blind, double-dummy, placebo-controlled, crossover study to evaluate the efficacy of TREXIMET (sumatriptan + naproxen sodium) versus Butalbital-Containing Combination Medications (BCM) for the acute treatment of migraine when administered during the moderate-severe pain phase of the migraine (pooled data), 2010. download.gsk-clinicalstudyregister.com/files/21144.pdf (accessed 23 September 2013). DerosierF , SheftellF , SilbersteinS , CadyR , RuoffG , KrishenA , et al. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache2012;52(4):530-43. [DOI: 10.1111/j.1526-4610.2011.02039.x]">TRX109011/13</a>); there were insufficient data for a head‐to‐head analysis of the active comparator from this single trial. There were no other active comparators. In total, 3663 participants who took sumatriptan plus naproxen were included in safety analyses for adverse events; 3682 took placebo, 964 took sumatriptan alone, 982 took naproxen alone, and 304 took a combination medication containing butalbital 50 mg, paracetamol (acetaminophen) 325 mg, and caffeine 40 mg. The number included in efficacy analyses was slightly lower because some participants were excluded from these analyses due to protocol violations, and <a href="./references#CD008541-bbs2-0003" title="CalhounAH , FordS . Double-blind, placebo-controlled, crossover study of early-intervention with sumatriptan 85/naproxen sodium 500 in (truly) episodic migraine: what's neck pain got to do with it?Postgraduate Medicine2014;126(2):86-90. [DOI: 10.3810/pgm.2014.03.2743]">Calhoun 2014</a> did not provide data for pooled analyses. </p> <p>The outcomes reported by individual studies are listed in the <a href="./references#CD008541-sec-0120" title="">Characteristics of included studies</a> table. All studies included in the pooled analyses measured headache PI using a standard 4‐point scale, and evaluated pain‐free response at two hours and sustained pain‐free during the 24 hours post dose as the primary outcome measures. Of the four studies treating headache of moderate or severe intensity, all measured headache relief at two hours and sustained headache relief during the 24 hours post dose (<a href="./references#CD008541-bbs2-0001" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 1;</a><a href="./references#CD008541-bbs2-0002" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 2</a>; <a href="./references#CD008541-bbs2-0012" title="SmithTR , SunshineA , StarkSR , LittlefieldDE , SpruillSE , AlexanderWJ . Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache2005;45(8):983-91. [DOI: 10.1111/j.1526-4610.2005.05178.x]">Smith 2005</a>; <a href="./references#CD008541-bbs2-0013" title="A randomized, double-blind, double-dummy, placebo-controlled, crossover study to evaluate the efficacy of TREXIMET (sumatriptan + naproxen sodium) versus Butalbital-Containing Combination Medications (BCM) for the acute treatment of migraine when administered during the moderate-severe pain phase of the migraine (pooled data), 2010. download.gsk-clinicalstudyregister.com/files/21144.pdf (accessed 23 September 2013). DerosierF , SheftellF , SilbersteinS , CadyR , RuoffG , KrishenA , et al. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache2012;52(4):530-43. [DOI: 10.1111/j.1526-4610.2011.02039.x]">TRX109011/13</a>), with <a href="./references#CD008541-bbs2-0012" title="SmithTR , SunshineA , StarkSR , LittlefieldDE , SpruillSE , AlexanderWJ . Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache2005;45(8):983-91. [DOI: 10.1111/j.1526-4610.2005.05178.x]">Smith 2005</a> also reporting headache relief at the earlier time of one hour. All studies reported on adverse events. <a href="./references#CD008541-bbs2-0003" title="CalhounAH , FordS . Double-blind, placebo-controlled, crossover study of early-intervention with sumatriptan 85/naproxen sodium 500 in (truly) episodic migraine: what's neck pain got to do with it?Postgraduate Medicine2014;126(2):86-90. [DOI: 10.3810/pgm.2014.03.2743]">Calhoun 2014</a> reported the outcome 'pain relief' as being a 2‐point decrease in pain intensity, but did not specify the tool used to measure pain intensity. </p> <p>Details of individual studies are in the <a href="./references#CD008541-sec-0120" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD008541-sec-0043"> <h4 class="title">Excluded studies</h4> <p>We excluded eight studies (nine publications) (<a href="./references#CD008541-bbs2-0014" title="CadyR , O'CarrollP , DexterK , FreitagF , ShadeCL . SumaRT/nap vs naproxen sodium in treatment and disease modification of migraine: a pilot study. Headache2014;54(1):67-79. [DOI: 10.1111/head.12211]">Cady 2014</a>; <a href="./references#CD008541-bbs2-0015" title="EdwardsKR , RosenthalBL , FarmerKU , CadyRK , BrowningR . Evaluation of sumatriptan-naproxen in the treatment of acute migraine: a placebo-controlled, double-blind, cross-over study assessing cognitive function. Headache2013;53(4):656-64. [DOI: 10.1111/head.12052]">Edwards 2013</a>; <a href="./references#CD008541-bbs2-0016" title="KrymchantowskiA . Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arquivos de Neuro-psiquiatria2000;58(2-B):428-30. ">Krymchantowski 2000</a>; <a href="./references#CD008541-bbs2-0017" title="LandyS , WhiteJ , LenerSE , McDonaldSA . Fixed-dose sumatriptan/naproxen sodium compared with each monotherapy utilizing the novel composite endpoint of sustained pain-free/no adverse events. Therapeutic Advances in Neurological Disorders2009;2(3):135. [DOI: 10.1177/1756285609102769]">Landy 2009</a>; <a href="./references#CD008541-bbs2-0018" title="SmithT , BlumenthalH , DiamondM , MauskopA , AmesM , McDonaldS , et al. Sumatriptan/naproxen sodium for migraine: efficacy, health related quality of life and satisfaction outcomes. Headache2007;47(5):683-92. ">Smith 2007</a>; <a href="./references#CD008541-bbs2-0019" title="Glazo Smith Kline study register. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and tolerability of TREXIMET (sumatriptan 85mg and naproxen sodium 500mg) for a single moderate or severe headache in adults diagnosed with probable migraine without aura. www.clinicaltrials.gov/ct2/show/NCT00387881 (accessed 23 September 2013). SilbersteinS , McDonaldSA , GoldsteinJ , AuroraS , LenerSE , WhiteJ , et al. Sumatriptan/naproxen sodium for the acute treatment of probable migraine without aura: a randomized study. Cephalalgia2014;34(4):268-79. [DOI: 10.1177/0333102413508242]">TRX107563</a> (and Silberstein 2014); <a href="./references#CD008541-bbs2-0020" title="WhiteW , DeposierF , ThompsonA , AdamsB , GoodmanD . Evaluation of the migraine treatment sumatriptan/naproxen on blood pressure following long term administration. Journal of Clinical Hypertension2011;13(12):910-6. ">White 2011</a>; <a href="./references#CD008541-bbs2-0021" title="WinnerP , CadyRK , RuoffGE , FrishbergBM , AlexanderWJ , ZhangY , et al. Twelve month tolerability and safety of sumatriptan-naproxen sodium for the treatment of acute migraine. Mayo Clinic Proceedings2007;82(1):61-8. ">Winner 2007</a>). Details are in the <a href="./references#CD008541-sec-0121" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD008541-sec-0044"> <h3 class="title">Risk of bias in included studies</h3> <p>Methodological quality, assessed using the Oxford Quality Scale, was good in all studies. Three studies scored 5/5 (<a href="./references#CD008541-bbs2-0010" title="SilbersteinSD , MannixLK , GoldsteinJ , CouchJR , ByrdSC , AmesMH , et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology2008;71(2):114-21. [DOI: 10.1212/01.wnl.0000316800.22949.20]TaylorFR , HeiringJO , MessinaE , Braverman-PanzaJ , AmesMH , ByrdSC , et al. Sumatriptan/naproxen sodium as early intervention for migraine: effects on functional ability, productivity, and satisfaction in 2 randomized controlled trials. Journal of Clinical Outcomes Management2007;14(4):195-204. ">Silberstein 2008 Study 1;</a><a href="./references#CD008541-bbs2-0011" title="SilbersteinSD , MannixLK , GoldsteinJ , CouchJR , ByrdSC , AmesMH , et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology2008;71(2):114-21. [DOI: 10.1212/01.wnl.0000316800.22949.20]TaylorFR , HeiringJO , MessinaE , Braverman-PanzaJ , AmesMH , ByrdSC , et al. Sumatriptan/naproxen sodium as early intervention for migraine: effects on functional ability, productivity, and satisfaction in 2 randomized controlled trials. Journal of Clinical Outcomes Management2007;14(4):195-204. ">Silberstein 2008 Study 2</a>; <a href="./references#CD008541-bbs2-0013" title="A randomized, double-blind, double-dummy, placebo-controlled, crossover study to evaluate the efficacy of TREXIMET (sumatriptan + naproxen sodium) versus Butalbital-Containing Combination Medications (BCM) for the acute treatment of migraine when administered during the moderate-severe pain phase of the migraine (pooled data), 2010. download.gsk-clinicalstudyregister.com/files/21144.pdf (accessed 23 September 2013). DerosierF , SheftellF , SilbersteinS , CadyR , RuoffG , KrishenA , et al. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache2012;52(4):530-43. [DOI: 10.1111/j.1526-4610.2011.02039.x]">TRX109011/13</a>), three scored 4/5 (<a href="./references#CD008541-bbs2-0006" title="CadyRK , DiamondML , DiamondMP , BallardJE , LenerME , DornerDP , et al. Sumatriptan - naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache2011;51(5):664-73. [DOI: 10.1111/j.1526-4610.2011.01894.x]MannixLK , MartinVT , CadyRK , DiamondML , LenerSE , WhiteJD , et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Journal of Obstetrics and Gynecology2009;114(1):106-13. [DOI: 10.1097/AOG.0b013e3181a98e4d]MartinVT , BallardJ , DiamondMP , MannixLK , DerosierFJ , LenerSE , et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Journal of Women's Health2014;23(5):389-96. [DOI: 10.1089/jwh.2013.4577]">Mannix 2009 Study 1</a>; <a href="./references#CD008541-bbs2-0007" title="CadyRK , DiamondML , DiamondMP , BallardJE , LenerME , DornerDP , et al. Sumatriptan - naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache2011;51(5):664-73. [DOI: 10.1111/j.1526-4610.2011.01894.x]MannixLK , MartinVT , CadyRK , DiamondML , LenerSE , WhiteJD , et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Journal of Obstetrics and Gynecology2009;114(1):106-13. [DOI: 10.1097/AOG.0b013e3181a98e4d]MartinVT , BallardJ , DiamondMP , MannixLK , DerosierFJ , LenerSE , et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Journal of Women's Health2014;23(5):389-96. [DOI: 10.1089/jwh.2013.4577]">Mannix 2009 Study 2</a>; <a href="./references#CD008541-bbs2-0018" title="SmithT , BlumenthalH , DiamondM , MauskopA , AmesM , McDonaldS , et al. Sumatriptan/naproxen sodium for migraine: efficacy, health related quality of life and satisfaction outcomes. Headache2007;47(5):683-92. ">Smith 2007</a>), and seven scored 3/5 (<a href="./references#CD008541-bbs2-0001" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 1</a>; <a href="./references#CD008541-bbs2-0002" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 2</a>; <a href="./references#CD008541-bbs2-0003" title="CalhounAH , FordS . Double-blind, placebo-controlled, crossover study of early-intervention with sumatriptan 85/naproxen sodium 500 in (truly) episodic migraine: what's neck pain got to do with it?Postgraduate Medicine2014;126(2):86-90. [DOI: 10.3810/pgm.2014.03.2743]">Calhoun 2014</a>; <a href="./references#CD008541-bbs2-0004" title="LandySH , CadyRK , NelsenA , WhiteJ , RunkenMC . Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination. Headache2014;54(4):640-54. [DOI: 10.1111/head.12214]LiptonRB , DodickDW , AdelmanJU , KanieckiRG , LenerSE , WhiteJD , et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia2009;29(8):826-36. [DOI: 10.1111/j.1468-2982.2008.01806.x]">Lipton 2009 Study 1</a>; <a href="./references#CD008541-bbs2-0005" title="LandySH , CadyRK , NelsenA , WhiteJ , RunkenMC . Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination. Headache2014;54(4):640-54. [DOI: 10.1111/head.12214]LiptonRB , DodickDW , AdelmanJU , KanieckiRG , LenerSE , WhiteJD , et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia2009;29(8):826-36. [DOI: 10.1111/j.1468-2982.2008.01806.x]">Lipton 2009 Study 2</a>; <a href="./references#CD008541-bbs2-0008" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 1</a>; <a href="./references#CD008541-bbs2-0009" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 2</a>). Points were lost mainly due to failure to report the method of randomisation or blinding adequately. Full details are in the <a href="./references#CD008541-sec-0120" title="">Characteristics of included studies</a> table. </p> <p>We also completed a 'Risk of bias' assessment. Studies were generally of a very high standard, but frequently failed to report details of the methods used to reduce bias (randomisation, allocation concealment, blinding). It is likely that this is an omission in reporting rather than a deficiency in methods (<a href="#CD008541-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD008541-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008541-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD008541-sec-0045"> <h4 class="title">Allocation</h4> <p>All studies stated that they were randomised but only six adequately described the methods used to generate the random sequence (<a href="./references#CD008541-bbs2-0003" title="CalhounAH , FordS . Double-blind, placebo-controlled, crossover study of early-intervention with sumatriptan 85/naproxen sodium 500 in (truly) episodic migraine: what's neck pain got to do with it?Postgraduate Medicine2014;126(2):86-90. [DOI: 10.3810/pgm.2014.03.2743]">Calhoun 2014</a>; <a href="./references#CD008541-bbs2-0006" title="CadyRK , DiamondML , DiamondMP , BallardJE , LenerME , DornerDP , et al. Sumatriptan - naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache2011;51(5):664-73. [DOI: 10.1111/j.1526-4610.2011.01894.x]MannixLK , MartinVT , CadyRK , DiamondML , LenerSE , WhiteJD , et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Journal of Obstetrics and Gynecology2009;114(1):106-13. [DOI: 10.1097/AOG.0b013e3181a98e4d]MartinVT , BallardJ , DiamondMP , MannixLK , DerosierFJ , LenerSE , et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Journal of Women's Health2014;23(5):389-96. [DOI: 10.1089/jwh.2013.4577]">Mannix 2009 Study 1</a>; <a href="./references#CD008541-bbs2-0007" title="CadyRK , DiamondML , DiamondMP , BallardJE , LenerME , DornerDP , et al. Sumatriptan - naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache2011;51(5):664-73. [DOI: 10.1111/j.1526-4610.2011.01894.x]MannixLK , MartinVT , CadyRK , DiamondML , LenerSE , WhiteJD , et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Journal of Obstetrics and Gynecology2009;114(1):106-13. [DOI: 10.1097/AOG.0b013e3181a98e4d]MartinVT , BallardJ , DiamondMP , MannixLK , DerosierFJ , LenerSE , et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Journal of Women's Health2014;23(5):389-96. [DOI: 10.1089/jwh.2013.4577]">Mannix 2009 Study 2</a>; <a href="./references#CD008541-bbs2-0010" title="SilbersteinSD , MannixLK , GoldsteinJ , CouchJR , ByrdSC , AmesMH , et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology2008;71(2):114-21. [DOI: 10.1212/01.wnl.0000316800.22949.20]TaylorFR , HeiringJO , MessinaE , Braverman-PanzaJ , AmesMH , ByrdSC , et al. Sumatriptan/naproxen sodium as early intervention for migraine: effects on functional ability, productivity, and satisfaction in 2 randomized controlled trials. Journal of Clinical Outcomes Management2007;14(4):195-204. ">Silberstein 2008 Study 1</a>; <a href="./references#CD008541-bbs2-0011" title="SilbersteinSD , MannixLK , GoldsteinJ , CouchJR , ByrdSC , AmesMH , et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology2008;71(2):114-21. [DOI: 10.1212/01.wnl.0000316800.22949.20]TaylorFR , HeiringJO , MessinaE , Braverman-PanzaJ , AmesMH , ByrdSC , et al. Sumatriptan/naproxen sodium as early intervention for migraine: effects on functional ability, productivity, and satisfaction in 2 randomized controlled trials. Journal of Clinical Outcomes Management2007;14(4):195-204. ">Silberstein 2008 Study 2</a>; <a href="./references#CD008541-bbs2-0013" title="A randomized, double-blind, double-dummy, placebo-controlled, crossover study to evaluate the efficacy of TREXIMET (sumatriptan + naproxen sodium) versus Butalbital-Containing Combination Medications (BCM) for the acute treatment of migraine when administered during the moderate-severe pain phase of the migraine (pooled data), 2010. download.gsk-clinicalstudyregister.com/files/21144.pdf (accessed 23 September 2013). DerosierF , SheftellF , SilbersteinS , CadyR , RuoffG , KrishenA , et al. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache2012;52(4):530-43. [DOI: 10.1111/j.1526-4610.2011.02039.x]">TRX109011/13</a>) and only two described the method used to conceal allocation (<a href="./references#CD008541-bbs2-0006" title="CadyRK , DiamondML , DiamondMP , BallardJE , LenerME , DornerDP , et al. Sumatriptan - naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache2011;51(5):664-73. [DOI: 10.1111/j.1526-4610.2011.01894.x]MannixLK , MartinVT , CadyRK , DiamondML , LenerSE , WhiteJD , et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Journal of Obstetrics and Gynecology2009;114(1):106-13. [DOI: 10.1097/AOG.0b013e3181a98e4d]MartinVT , BallardJ , DiamondMP , MannixLK , DerosierFJ , LenerSE , et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Journal of Women's Health2014;23(5):389-96. [DOI: 10.1089/jwh.2013.4577]">Mannix 2009 Study 1</a>; <a href="./references#CD008541-bbs2-0007" title="CadyRK , DiamondML , DiamondMP , BallardJE , LenerME , DornerDP , et al. Sumatriptan - naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache2011;51(5):664-73. [DOI: 10.1111/j.1526-4610.2011.01894.x]MannixLK , MartinVT , CadyRK , DiamondML , LenerSE , WhiteJD , et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Journal of Obstetrics and Gynecology2009;114(1):106-13. [DOI: 10.1097/AOG.0b013e3181a98e4d]MartinVT , BallardJ , DiamondMP , MannixLK , DerosierFJ , LenerSE , et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Journal of Women's Health2014;23(5):389-96. [DOI: 10.1089/jwh.2013.4577]">Mannix 2009 Study 2</a>). </p> </section> <section id="CD008541-sec-0046"> <h4 class="title">Blinding</h4> <p>All studies reported that they were double‐blind, but only four adequately described the methods used to maintain blinding (<a href="./references#CD008541-bbs2-0010" title="SilbersteinSD , MannixLK , GoldsteinJ , CouchJR , ByrdSC , AmesMH , et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology2008;71(2):114-21. [DOI: 10.1212/01.wnl.0000316800.22949.20]TaylorFR , HeiringJO , MessinaE , Braverman-PanzaJ , AmesMH , ByrdSC , et al. Sumatriptan/naproxen sodium as early intervention for migraine: effects on functional ability, productivity, and satisfaction in 2 randomized controlled trials. Journal of Clinical Outcomes Management2007;14(4):195-204. ">Silberstein 2008 Study 1</a>; <a href="./references#CD008541-bbs2-0011" title="SilbersteinSD , MannixLK , GoldsteinJ , CouchJR , ByrdSC , AmesMH , et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology2008;71(2):114-21. [DOI: 10.1212/01.wnl.0000316800.22949.20]TaylorFR , HeiringJO , MessinaE , Braverman-PanzaJ , AmesMH , ByrdSC , et al. Sumatriptan/naproxen sodium as early intervention for migraine: effects on functional ability, productivity, and satisfaction in 2 randomized controlled trials. Journal of Clinical Outcomes Management2007;14(4):195-204. ">Silberstein 2008 Study 2</a>; <a href="./references#CD008541-bbs2-0012" title="SmithTR , SunshineA , StarkSR , LittlefieldDE , SpruillSE , AlexanderWJ . Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache2005;45(8):983-91. [DOI: 10.1111/j.1526-4610.2005.05178.x]">Smith 2005</a>; <a href="./references#CD008541-bbs2-0013" title="A randomized, double-blind, double-dummy, placebo-controlled, crossover study to evaluate the efficacy of TREXIMET (sumatriptan + naproxen sodium) versus Butalbital-Containing Combination Medications (BCM) for the acute treatment of migraine when administered during the moderate-severe pain phase of the migraine (pooled data), 2010. download.gsk-clinicalstudyregister.com/files/21144.pdf (accessed 23 September 2013). DerosierF , SheftellF , SilbersteinS , CadyR , RuoffG , KrishenA , et al. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache2012;52(4):530-43. [DOI: 10.1111/j.1526-4610.2011.02039.x]">TRX109011/13</a>). </p> </section> <section id="CD008541-sec-0047"> <h4 class="title">Incomplete outcome data</h4> <p>All studies accounted for all participants except <a href="./references#CD008541-bbs2-0003" title="CalhounAH , FordS . Double-blind, placebo-controlled, crossover study of early-intervention with sumatriptan 85/naproxen sodium 500 in (truly) episodic migraine: what's neck pain got to do with it?Postgraduate Medicine2014;126(2):86-90. [DOI: 10.3810/pgm.2014.03.2743]">Calhoun 2014</a>, in which the denominator used for calculating per cent response was unclear. This study did not contribute to any analyses. Other studies did not have substantial amounts of missing data. </p> </section> <section id="CD008541-sec-0048"> <h4 class="title">Other potential sources of bias</h4> <p>We judged <a href="./references#CD008541-bbs2-0003" title="CalhounAH , FordS . Double-blind, placebo-controlled, crossover study of early-intervention with sumatriptan 85/naproxen sodium 500 in (truly) episodic migraine: what's neck pain got to do with it?Postgraduate Medicine2014;126(2):86-90. [DOI: 10.3810/pgm.2014.03.2743]">Calhoun 2014</a> to be at high risk of bias due to its small size (fewer than 50 participants per treatment arm), but this study did not contribute to any analyses. We judged the remaining studies to be at unknown or low risk of bias due to their size. </p> </section> </section> <section id="CD008541-sec-0049"> <h3 class="title" id="CD008541-sec-0049">Effects of interventions</h3> <p>See: <a href="./full#CD008541-tbl-0001"><b>Summary of findings 1</b> Sumatriptan 50 mg or 85 mg plus naproxen 500 mg compared with placebo for migraine headache</a> </p> <p>Studies treating headache early, when pain was still mild, were analysed separately from those treating only once pain was of moderate or severe intensity. For analysis, we chose to combine results from the study using sumatriptan 50 mg plus naproxen 500 mg, given as separate tablets, with studies that used sumatriptan 85 mg plus naproxen 500 mg, given as a combined formulation. We carried out sensitivity analyses to determine the effect of the combined formulation alone. </p> <p>Details of the main efficacy outcomes in individual studies are in <a href="./appendices#CD008541-sec-0104">Appendix 6</a>, and of adverse events and withdrawals are in <a href="./appendices#CD008541-sec-0105">Appendix 7</a>. Results for pain‐free and headache relief outcomes are summarised in Summary of results: Pain‐free and headache relief. A summary of the main results, together with a judgement on the quality of the evidence for each outcome, is presented in <a href="./full#CD008541-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD008541-sec-0050"> <h4 class="title">Pain‐free at two hours</h4> <section id="CD008541-sec-0051"> <h5 class="title">Sumatriptan plus naproxen versus placebo</h5> <section id="CD008541-sec-0052"> <h6 class="title">Mild baseline pain</h6> <p>Eight studies (3395 attacks) provided data for early use of the combined formulation, compared with placebo, when pain was still mild (<a href="./references#CD008541-bbs2-0004" title="LandySH , CadyRK , NelsenA , WhiteJ , RunkenMC . Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination. Headache2014;54(4):640-54. [DOI: 10.1111/head.12214]LiptonRB , DodickDW , AdelmanJU , KanieckiRG , LenerSE , WhiteJD , et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia2009;29(8):826-36. [DOI: 10.1111/j.1468-2982.2008.01806.x]">Lipton 2009 Study 1</a>; <a href="./references#CD008541-bbs2-0005" title="LandySH , CadyRK , NelsenA , WhiteJ , RunkenMC . Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination. Headache2014;54(4):640-54. [DOI: 10.1111/head.12214]LiptonRB , DodickDW , AdelmanJU , KanieckiRG , LenerSE , WhiteJD , et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia2009;29(8):826-36. [DOI: 10.1111/j.1468-2982.2008.01806.x]">Lipton 2009 Study 2</a>; <a href="./references#CD008541-bbs2-0006" title="CadyRK , DiamondML , DiamondMP , BallardJE , LenerME , DornerDP , et al. Sumatriptan - naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache2011;51(5):664-73. [DOI: 10.1111/j.1526-4610.2011.01894.x]MannixLK , MartinVT , CadyRK , DiamondML , LenerSE , WhiteJD , et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Journal of Obstetrics and Gynecology2009;114(1):106-13. [DOI: 10.1097/AOG.0b013e3181a98e4d]MartinVT , BallardJ , DiamondMP , MannixLK , DerosierFJ , LenerSE , et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Journal of Women's Health2014;23(5):389-96. [DOI: 10.1089/jwh.2013.4577]">Mannix 2009 Study 1;</a><a href="./references#CD008541-bbs2-0007" title="CadyRK , DiamondML , DiamondMP , BallardJE , LenerME , DornerDP , et al. Sumatriptan - naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache2011;51(5):664-73. [DOI: 10.1111/j.1526-4610.2011.01894.x]MannixLK , MartinVT , CadyRK , DiamondML , LenerSE , WhiteJD , et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Journal of Obstetrics and Gynecology2009;114(1):106-13. [DOI: 10.1097/AOG.0b013e3181a98e4d]MartinVT , BallardJ , DiamondMP , MannixLK , DerosierFJ , LenerSE , et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Journal of Women's Health2014;23(5):389-96. [DOI: 10.1089/jwh.2013.4577]">Mannix 2009 Study 2</a>; <a href="./references#CD008541-bbs2-0008" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 1</a>; <a href="./references#CD008541-bbs2-0009" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 2</a>; <a href="./references#CD008541-bbs2-0010" title="SilbersteinSD , MannixLK , GoldsteinJ , CouchJR , ByrdSC , AmesMH , et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology2008;71(2):114-21. [DOI: 10.1212/01.wnl.0000316800.22949.20]TaylorFR , HeiringJO , MessinaE , Braverman-PanzaJ , AmesMH , ByrdSC , et al. Sumatriptan/naproxen sodium as early intervention for migraine: effects on functional ability, productivity, and satisfaction in 2 randomized controlled trials. Journal of Clinical Outcomes Management2007;14(4):195-204. ">Silberstein 2008 Study 1;</a><a href="./references#CD008541-bbs2-0011" title="SilbersteinSD , MannixLK , GoldsteinJ , CouchJR , ByrdSC , AmesMH , et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology2008;71(2):114-21. [DOI: 10.1212/01.wnl.0000316800.22949.20]TaylorFR , HeiringJO , MessinaE , Braverman-PanzaJ , AmesMH , ByrdSC , et al. Sumatriptan/naproxen sodium as early intervention for migraine: effects on functional ability, productivity, and satisfaction in 2 randomized controlled trials. Journal of Clinical Outcomes Management2007;14(4):195-204. ">Silberstein 2008 Study 2</a>). </p> <p> <ul id="CD008541-list-0009"> <li> <p>The proportion of attacks pain‐free at two hours with sumatriptan plus naproxen 85/500 mg was 50% (1008/2025; range 40% to 52%). </p> </li> <li> <p>The proportion of attacks pain‐free at two hours with placebo was 18% (244/1370; range 14% to 23%). </p> </li> <li> <p>The relative benefit of treatment compared with placebo was 2.8 (95% CI 2.4 to 3.1) (<a href="#CD008541-fig-0003">Figure 3</a>); the NNT was 3.1 (95% CI 2.9 to 3.5). </p> </li> </ul> </p> <div class="figure" id="CD008541-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Sumatriptan plus naproxen versus placebo, outcome: 1.1 Pain‐free at two hours." data-id="CD008541-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Sumatriptan plus naproxen versus placebo, outcome: 1.1 Pain‐free at two hours. </p> </div> </div> </div> <p><a href="./references#CD008541-bbs2-0003" title="CalhounAH , FordS . Double-blind, placebo-controlled, crossover study of early-intervention with sumatriptan 85/naproxen sodium 500 in (truly) episodic migraine: what's neck pain got to do with it?Postgraduate Medicine2014;126(2):86-90. [DOI: 10.3810/pgm.2014.03.2743]">Calhoun 2014</a> reported a response rate of 64% with sumatriptan plus naproxen and 33% with placebo for this outcome in participants who experienced fewer than eight days/month with migraine headache or 15 days/month with migraine headache <b>or</b> neck pain. Data from six attacks were missing due to the participant being asleep at two hours; these attacks were not counted as 'pain‐free at two hours' responses. </p> </section> <section id="CD008541-sec-0053"> <h6 class="title">Moderate or severe baseline pain</h6> <p>Four studies (2596 attacks) provided data for use of either the combined formulation (<a href="./references#CD008541-bbs2-0001" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 1;</a><a href="./references#CD008541-bbs2-0002" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 2</a>; <a href="./references#CD008541-bbs2-0013" title="A randomized, double-blind, double-dummy, placebo-controlled, crossover study to evaluate the efficacy of TREXIMET (sumatriptan + naproxen sodium) versus Butalbital-Containing Combination Medications (BCM) for the acute treatment of migraine when administered during the moderate-severe pain phase of the migraine (pooled data), 2010. download.gsk-clinicalstudyregister.com/files/21144.pdf (accessed 23 September 2013). DerosierF , SheftellF , SilbersteinS , CadyR , RuoffG , KrishenA , et al. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache2012;52(4):530-43. [DOI: 10.1111/j.1526-4610.2011.02039.x]">TRX109011/13</a>), or separate tablets (<a href="./references#CD008541-bbs2-0012" title="SmithTR , SunshineA , StarkSR , LittlefieldDE , SpruillSE , AlexanderWJ . Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache2005;45(8):983-91. [DOI: 10.1111/j.1526-4610.2005.05178.x]">Smith 2005</a>), compared with placebo, when pain was moderate or severe. </p> <p> <ul id="CD008541-list-0010"> <li> <p>The proportion of attacks pain‐free at two hours with sumatriptan plus naproxen 50 to 85/500 mg was 28% (362/1293; range 14% to 34%). </p> </li> <li> <p>The proportion of attacks pain‐free at two hours with placebo was 7.7% (100/1303; range 5% to 10%). </p> </li> <li> <p>The relative benefit of treatment compared with placebo was 3.7 (95% CI 3.0 to 4.5) (<a href="#CD008541-fig-0003">Figure 3</a>); the NNT was 4.9 (95% CI 4.3 to 5.7). </p> </li> <li> <p>For sumatriptan plus naproxen 85/500 mg only (excluding the 50/500 mg dose), the NNT was 5.4 (95% CI 4.6 to 6.5), which was not significantly different from the NNT for the combined analysis. </p> </li> </ul> </p> <p>Treating headache early, when pain was still mild, was significantly better than treating once pain was of moderate or severe intensity (z = 5.548; P value &lt; 0.00001). A L'Abbé plot shows no evidence of heterogeneity within each group (<a href="#CD008541-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD008541-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="L'Abbé plot showing results for sumatriptan plus naproxen versus placebo for pain‐free at two hours. Each circle represents a different study; blue circles are studies with moderate or severe baseline pain and cream circles are mild baseline pain; size of circle is proportional to size of study; diagonal is line of equivalence." data-id="CD008541-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-FIG-04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>L'Abbé plot showing results for sumatriptan plus naproxen versus placebo for pain‐free at two hours. Each circle represents a different study; blue circles are studies with moderate or severe baseline pain and cream circles are mild baseline pain; size of circle is proportional to size of study; diagonal is line of equivalence. </p> </div> </div> </div> </section> </section> <section id="CD008541-sec-0054"> <h5 class="title">Sumatriptan plus naproxen versus sumatriptan or naproxen alone</h5> <p>Three studies provided data for use of either the combined formulation (<a href="./references#CD008541-bbs2-0001" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 1;</a><a href="./references#CD008541-bbs2-0002" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 2</a>) or separate tablets (<a href="./references#CD008541-bbs2-0012" title="SmithTR , SunshineA , StarkSR , LittlefieldDE , SpruillSE , AlexanderWJ . Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache2005;45(8):983-91. [DOI: 10.1111/j.1526-4610.2005.05178.x]">Smith 2005</a>), compared with sumatriptan alone (1925 participants) or naproxen alone (1944 participants), when pain was moderate or severe. </p> <p> <ul id="CD008541-list-0011"> <li> <p>The proportion of participants pain‐free at two hours with sumatriptan plus naproxen 50 to 85/500 mg was 32% (317/976; range 30% to 34%). </p> </li> <li> <p>The proportion of participants pain‐free at two hours with sumatriptan alone was 23% (217/949; range 20% to 25%). </p> </li> <li> <p>The proportion of participants pain‐free at two hours with naproxen alone was 16% (155/968; range 15% to 18%). </p> </li> <li> <p>The relative benefit of the combination compared with sumatriptan alone was 1.4 (95% CI 1.2 to 1.7) (<a href="./references#CD008541-fig-0016" title="">Analysis 2.1</a>); the NNT was 10 (95% CI 7.4 to 18). </p> </li> <li> <p>The relative benefit of the combination compared with naproxen alone was 2.0 (95% CI 1.7 to 2.4) (<a href="./references#CD008541-fig-0024" title="">Analysis 3.1</a>); the NNT was 6.1 (95% CI 5.0 to 7.9). </p> </li> </ul> </p> <p>The combination was significantly better than either sumatriptan or naproxen alone.</p> </section> </section> <section id="CD008541-sec-0055"> <h4 class="title">Headache relief at two hours</h4> <section id="CD008541-sec-0056"> <h5 class="title">Sumatriptan plus naproxen versus placebo</h5> <p>Four studies (2596 attacks) provided data for use of either the combined formulation (<a href="./references#CD008541-bbs2-0001" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 1;</a><a href="./references#CD008541-bbs2-0002" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 2</a>; <a href="./references#CD008541-bbs2-0013" title="A randomized, double-blind, double-dummy, placebo-controlled, crossover study to evaluate the efficacy of TREXIMET (sumatriptan + naproxen sodium) versus Butalbital-Containing Combination Medications (BCM) for the acute treatment of migraine when administered during the moderate-severe pain phase of the migraine (pooled data), 2010. download.gsk-clinicalstudyregister.com/files/21144.pdf (accessed 23 September 2013). DerosierF , SheftellF , SilbersteinS , CadyR , RuoffG , KrishenA , et al. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache2012;52(4):530-43. [DOI: 10.1111/j.1526-4610.2011.02039.x]">TRX109011/13</a>), or separate tablets (<a href="./references#CD008541-bbs2-0012" title="SmithTR , SunshineA , StarkSR , LittlefieldDE , SpruillSE , AlexanderWJ . Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache2005;45(8):983-91. [DOI: 10.1111/j.1526-4610.2005.05178.x]">Smith 2005</a>), compared with placebo, when pain was moderate or severe. </p> <p> <ul id="CD008541-list-0012"> <li> <p>The proportion of attacks with headache relief at two hours with sumatriptan plus naproxen 50 to 85/500 mg was 58% (755/1293; range 47% to 65%). </p> </li> <li> <p>The proportion of attacks with headache relief at two hours with placebo was 27% (352/1303; range 24% to 29%). </p> </li> <li> <p>The relative benefit of treatment compared with placebo was 2.2 (95% CI 2.0 to 2.4); the NNT was 3.2 (95% CI 2.9 to 3.6) (<a href="#CD008541-fig-0005">Figure 5</a>). </p> </li> <li> <p>For sumatriptan plus naproxen 85/500 mg alone (excluding the 50/500 mg dose) the NNT was 3.4 (95% CI 3.0 to 3.9), which was not significantly different from the NNT for the combined analysis. </p> </li> </ul> </p> <div class="figure" id="CD008541-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Sumatriptan plus naproxen versus placebo, outcome: 1.2 Headache relief at two hours." data-id="CD008541-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Sumatriptan plus naproxen versus placebo, outcome: 1.2 Headache relief at two hours. </p> </div> </div> </div> <p>A L'Abbé plot showed no evidence of heterogeneity between the studies (<a href="#CD008541-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD008541-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="L'Abbé plot showing results for sumatriptan plus naproxen versus placebo for headache relief at two hours in studies with moderate or severe baseline pain. Each circle represents a different study; size of circle is proportional to size of study; diagonal is line of equivalence." data-id="CD008541-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-FIG-06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>L'Abbé plot showing results for sumatriptan plus naproxen versus placebo for headache relief at two hours in studies with moderate or severe baseline pain. Each circle represents a different study; size of circle is proportional to size of study; diagonal is line of equivalence. </p> </div> </div> </div> </section> <section id="CD008541-sec-0057"> <h5 class="title">Sumatriptan plus naproxen versus sumatriptan or naproxen alone</h5> <p>Three studies provided data for use of either the combined formulation (<a href="./references#CD008541-bbs2-0001" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 1;</a><a href="./references#CD008541-bbs2-0002" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 2</a>), or separate tablets (<a href="./references#CD008541-bbs2-0012" title="SmithTR , SunshineA , StarkSR , LittlefieldDE , SpruillSE , AlexanderWJ . Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache2005;45(8):983-91. [DOI: 10.1111/j.1526-4610.2005.05178.x]">Smith 2005</a>), compared with sumatriptan alone (1925 participants) or naproxen alone (1944 participants), when pain was moderate or severe. </p> <p> <ul id="CD008541-list-0013"> <li> <p>The proportion of participants experiencing headache relief at two hours with sumatriptan plus naproxen 50 to 85/500 mg was 62% (607/976; range 57% to 65%). </p> </li> <li> <p>The proportion of participants experiencing headache relief at two hours with sumatriptan alone was 52% (493/949; range 49% to 55%). </p> </li> <li> <p>The proportion of participants experiencing headache relief at two hours with naproxen alone was 44% (426/968; range 43% to 45%). </p> </li> <li> <p>The relative benefit of the combination compared with sumatriptan alone was 1.2 (95% CI 1.1 to 1.3); the NNT was 9.8 (95% CI 6.8 to 17) (<a href="./references#CD008541-fig-0017" title="">Analysis 2.2</a>). </p> </li> <li> <p>The relative benefit of the combination compared with naproxen alone was 1.4 (95% CI 1.3 to 1.5); the NNT was 5.5 (95% CI 4.4 to 7.2) (<a href="./references#CD008541-fig-0025" title="">Analysis 3.2</a>). </p> </li> </ul> </p> <p>The combination was significantly better than either sumatriptan or naproxen alone.</p> </section> </section> <section id="CD008541-sec-0058"> <h4 class="title">Headache relief at one hour</h4> <p>One study treating moderate to severe baseline pain provided data (<a href="./references#CD008541-bbs2-0012" title="SmithTR , SunshineA , StarkSR , LittlefieldDE , SpruillSE , AlexanderWJ . Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache2005;45(8):983-91. [DOI: 10.1111/j.1526-4610.2005.05178.x]">Smith 2005</a>); 73/250 participants experienced headache relief with combination therapy compared with 52/226 with sumatriptan alone, 67/248 with naproxen alone, and 29/241 with placebo. The data were insufficient for analysis. </p> </section> <section id="CD008541-sec-0059"> <h4 class="title">Sustained pain‐free during the 24 hours post dose</h4> <section id="CD008541-sec-0060"> <h5 class="title">Sumatriptan plus naproxen versus placebo</h5> <section id="CD008541-sec-0061"> <h6 class="title">Mild baseline pain</h6> <p>Eight studies (3396 attacks) provided data (<a href="./references#CD008541-bbs2-0004" title="LandySH , CadyRK , NelsenA , WhiteJ , RunkenMC . Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination. Headache2014;54(4):640-54. [DOI: 10.1111/head.12214]LiptonRB , DodickDW , AdelmanJU , KanieckiRG , LenerSE , WhiteJD , et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia2009;29(8):826-36. [DOI: 10.1111/j.1468-2982.2008.01806.x]">Lipton 2009 Study 1</a>; <a href="./references#CD008541-bbs2-0005" title="LandySH , CadyRK , NelsenA , WhiteJ , RunkenMC . Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination. Headache2014;54(4):640-54. [DOI: 10.1111/head.12214]LiptonRB , DodickDW , AdelmanJU , KanieckiRG , LenerSE , WhiteJD , et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia2009;29(8):826-36. [DOI: 10.1111/j.1468-2982.2008.01806.x]">Lipton 2009 Study 2</a>; <a href="./references#CD008541-bbs2-0006" title="CadyRK , DiamondML , DiamondMP , BallardJE , LenerME , DornerDP , et al. Sumatriptan - naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache2011;51(5):664-73. [DOI: 10.1111/j.1526-4610.2011.01894.x]MannixLK , MartinVT , CadyRK , DiamondML , LenerSE , WhiteJD , et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Journal of Obstetrics and Gynecology2009;114(1):106-13. [DOI: 10.1097/AOG.0b013e3181a98e4d]MartinVT , BallardJ , DiamondMP , MannixLK , DerosierFJ , LenerSE , et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Journal of Women's Health2014;23(5):389-96. [DOI: 10.1089/jwh.2013.4577]">Mannix 2009 Study 1;</a><a href="./references#CD008541-bbs2-0007" title="CadyRK , DiamondML , DiamondMP , BallardJE , LenerME , DornerDP , et al. Sumatriptan - naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache2011;51(5):664-73. [DOI: 10.1111/j.1526-4610.2011.01894.x]MannixLK , MartinVT , CadyRK , DiamondML , LenerSE , WhiteJD , et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Journal of Obstetrics and Gynecology2009;114(1):106-13. [DOI: 10.1097/AOG.0b013e3181a98e4d]MartinVT , BallardJ , DiamondMP , MannixLK , DerosierFJ , LenerSE , et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Journal of Women's Health2014;23(5):389-96. [DOI: 10.1089/jwh.2013.4577]">Mannix 2009 Study 2</a>; <a href="./references#CD008541-bbs2-0008" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 1;</a><a href="./references#CD008541-bbs2-0009" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 2</a>; <a href="./references#CD008541-bbs2-0010" title="SilbersteinSD , MannixLK , GoldsteinJ , CouchJR , ByrdSC , AmesMH , et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology2008;71(2):114-21. [DOI: 10.1212/01.wnl.0000316800.22949.20]TaylorFR , HeiringJO , MessinaE , Braverman-PanzaJ , AmesMH , ByrdSC , et al. Sumatriptan/naproxen sodium as early intervention for migraine: effects on functional ability, productivity, and satisfaction in 2 randomized controlled trials. Journal of Clinical Outcomes Management2007;14(4):195-204. ">Silberstein 2008 Study 1;</a><a href="./references#CD008541-bbs2-0011" title="SilbersteinSD , MannixLK , GoldsteinJ , CouchJR , ByrdSC , AmesMH , et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology2008;71(2):114-21. [DOI: 10.1212/01.wnl.0000316800.22949.20]TaylorFR , HeiringJO , MessinaE , Braverman-PanzaJ , AmesMH , ByrdSC , et al. Sumatriptan/naproxen sodium as early intervention for migraine: effects on functional ability, productivity, and satisfaction in 2 randomized controlled trials. Journal of Clinical Outcomes Management2007;14(4):195-204. ">Silberstein 2008 Study 2</a>) for early use of the combined formulation, compared with placebo, when pain was still mild. </p> <p> <ul id="CD008541-list-0014"> <li> <p>The proportion of attacks with a 24‐hour sustained pain‐free response with sumatriptan plus naproxen 85/500 mg was 37% (741/2026; range 26% to 45%). </p> </li> <li> <p>The proportion of attacks with a 24‐hour sustained pain‐free response with placebo was 12% (166/1370; range 8% to 18%). </p> </li> <li> <p>The relative benefit of treatment compared with placebo was 3.0 (95% CI 2.6 to 3.6) (<a href="./references#CD008541-fig-0010" title="">Analysis 1.3</a>); the NNT was 4.1 (95% CI 3.7 to 4.6). </p> </li> </ul> </p> <p><a href="./references#CD008541-bbs2-0003" title="CalhounAH , FordS . Double-blind, placebo-controlled, crossover study of early-intervention with sumatriptan 85/naproxen sodium 500 in (truly) episodic migraine: what's neck pain got to do with it?Postgraduate Medicine2014;126(2):86-90. [DOI: 10.3810/pgm.2014.03.2743]">Calhoun 2014</a> reported a response rate of 69% with sumatriptan plus naproxen and 23% with placebo for this outcome in participants who experienced fewer than eight days/month with migraine headache or 15 days/month with migraine headache <b>or</b> neck pain. </p> </section> <section id="CD008541-sec-0062"> <h6 class="title">Moderate or severe baseline pain</h6> <p>Four studies (2596 attacks) provided data for use of either the combined formulation (<a href="./references#CD008541-bbs2-0001" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 1;</a><a href="./references#CD008541-bbs2-0002" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 2</a>; <a href="./references#CD008541-bbs2-0013" title="A randomized, double-blind, double-dummy, placebo-controlled, crossover study to evaluate the efficacy of TREXIMET (sumatriptan + naproxen sodium) versus Butalbital-Containing Combination Medications (BCM) for the acute treatment of migraine when administered during the moderate-severe pain phase of the migraine (pooled data), 2010. download.gsk-clinicalstudyregister.com/files/21144.pdf (accessed 23 September 2013). DerosierF , SheftellF , SilbersteinS , CadyR , RuoffG , KrishenA , et al. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache2012;52(4):530-43. [DOI: 10.1111/j.1526-4610.2011.02039.x]">TRX109011/13</a>), or separate tablets (<a href="./references#CD008541-bbs2-0012" title="SmithTR , SunshineA , StarkSR , LittlefieldDE , SpruillSE , AlexanderWJ . Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache2005;45(8):983-91. [DOI: 10.1111/j.1526-4610.2005.05178.x]">Smith 2005</a>), compared with placebo, when pain was moderate or severe. </p> <p> <ul id="CD008541-list-0015"> <li> <p>The proportion of attacks with a 24‐hour sustained pain‐free response with sumatriptan plus naproxen 50 to 85/500 mg was 20% (262/1293; range 8.2% to 25%). </p> </li> <li> <p>The proportion of attacks with a 24‐hour sustained pain‐free response with placebo was 5.9% (77/1303; range 3.1% to 8.3%). </p> </li> <li> <p>The relative benefit of treatment compared with placebo was 3.4 (95% CI 2.7 to 4.4) (<a href="./references#CD008541-fig-0010" title="">Analysis 1.3</a>); the NNT was 7.0 (95% CI 5.9 to 8.5). </p> </li> <li> <p>For sumatriptan plus naproxen 85/500 mg alone (excluding the 50/500 mg dose) the NNT was 7.7 (95% CI 6.4 to 9.8), which was not significantly different from the NNT for the combined analysis. </p> </li> </ul> </p> <p>Treating headache early, when pain was still mild, was significantly better than treating once pain was of moderate or severe intensity (z = 5.326; P value = 0.0001). A L'Abbé plot showed no evidence of heterogeneity between the studies, and there was considerable overlap between the two groups (<a href="#CD008541-fig-0007">Figure 7</a>). </p> <div class="figure" id="CD008541-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="L'Abbé plot showing results for sumatriptan plus naproxen versus placebo for 24‐hour sustained pain‐free. Each circle represents a different study; blue circles are studies with moderate or severe baseline pain and cream circles are mild baseline pain; size of circle is proportional to size of study; diagonal is line of equivalence." data-id="CD008541-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-FIG-07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>L'Abbé plot showing results for sumatriptan plus naproxen versus placebo for 24‐hour sustained pain‐free. Each circle represents a different study; blue circles are studies with moderate or severe baseline pain and cream circles are mild baseline pain; size of circle is proportional to size of study; diagonal is line of equivalence. </p> </div> </div> </div> </section> </section> <section id="CD008541-sec-0063"> <h5 class="title">Sumatriptan plus naproxen versus sumatriptan or naproxen alone</h5> <p>Three studies provided data for use of either the combined formulation (<a href="./references#CD008541-bbs2-0001" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 1;</a><a href="./references#CD008541-bbs2-0002" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 2</a>) or separate tablets (<a href="./references#CD008541-bbs2-0012" title="SmithTR , SunshineA , StarkSR , LittlefieldDE , SpruillSE , AlexanderWJ . Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache2005;45(8):983-91. [DOI: 10.1111/j.1526-4610.2005.05178.x]">Smith 2005</a>), compared with sumatriptan alone (1925 participants) or naproxen alone (1944 participants), when pain was moderate or severe. </p> <p> <ul id="CD008541-list-0016"> <li> <p>The proportion of participants with a 24‐hour sustained pain‐free response with sumatriptan plus naproxen 50 to 85/500 mg was 24% (236/976; range 23% to 25%). </p> </li> <li> <p>The proportion of participants with a 24‐hour sustained pain‐free response with sumatriptan alone was 14% (135/949; range 11% to 16%). </p> </li> <li> <p>The proportion of participants with a 24‐hour sustained pain‐free response with naproxen alone was 11% (104/968; range 10% to 12%). </p> </li> <li> <p>The relative benefit of the combination compared with sumatriptan alone was 1.7 (95% CI 1.4 to 2.1); the NNT was 10 (95% CI 7.4 to 15) (<a href="./references#CD008541-fig-0018" title="">Analysis 2.3</a>). </p> </li> <li> <p>The relative benefit of the combination compared with naproxen alone was 2.3 (95% CI 1.8 to 2.8); the NNT was 7.4 (95% CI 6.0 to 9.9) (<a href="./references#CD008541-fig-0026" title="">Analysis 3.3</a>). </p> </li> </ul> </p> <p>The combination was significantly better than either sumatriptan or naproxen alone.</p> </section> </section> <section id="CD008541-sec-0064"> <h4 class="title">Sustained headache relief during the 24 hours post dose</h4> <section id="CD008541-sec-0065"> <h5 class="title">Sumatriptan plus naproxen versus placebo</h5> <p>Four studies (2596 attacks) provided data for use of either the combined formulation (<a href="./references#CD008541-bbs2-0001" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 1</a>; <a href="./references#CD008541-bbs2-0002" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 2</a>; <a href="./references#CD008541-bbs2-0013" title="A randomized, double-blind, double-dummy, placebo-controlled, crossover study to evaluate the efficacy of TREXIMET (sumatriptan + naproxen sodium) versus Butalbital-Containing Combination Medications (BCM) for the acute treatment of migraine when administered during the moderate-severe pain phase of the migraine (pooled data), 2010. download.gsk-clinicalstudyregister.com/files/21144.pdf (accessed 23 September 2013). DerosierF , SheftellF , SilbersteinS , CadyR , RuoffG , KrishenA , et al. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache2012;52(4):530-43. [DOI: 10.1111/j.1526-4610.2011.02039.x]">TRX109011/13</a>), or separate tablets (<a href="./references#CD008541-bbs2-0012" title="SmithTR , SunshineA , StarkSR , LittlefieldDE , SpruillSE , AlexanderWJ . Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache2005;45(8):983-91. [DOI: 10.1111/j.1526-4610.2005.05178.x]">Smith 2005</a>), compared with placebo, when pain was moderate or severe. </p> <p> <ul id="CD008541-list-0017"> <li> <p>The proportion of attacks with 24‐hour sustained headache relief with sumatriptan plus naproxen 50 to 85/500 mg was 43% (554/1293; range 34% to 48%). </p> </li> <li> <p>The proportion of attacks with 24‐hour sustained headache relief with placebo was 16% (214/1303; range 14% to 18%). </p> </li> <li> <p>The relative benefit of treatment compared with placebo was 2.6 (95% CI 2.3 to 3.0) (<a href="./references#CD008541-fig-0011" title="">Analysis 1.4</a>); the NNT was 3.8 (95% CI 3.4 to 4.3). </p> </li> <li> <p>For sumatriptan plus naproxen 85/500 mg alone (excluding the 50/500 mg dose) the NNT was 3.9 (95% CI 3.4 to 4.5), which was not significantly different from the NNT for the combined analysis. </p> </li> </ul> </p> </section> <section id="CD008541-sec-0066"> <h5 class="title">Sumatriptan plus naproxen versus sumatriptan or naproxen alone</h5> <p>Three studies provided data for use of either the combined formulation (<a href="./references#CD008541-bbs2-0001" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 1</a>; <a href="./references#CD008541-bbs2-0002" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 2</a>), or separate tablets (<a href="./references#CD008541-bbs2-0012" title="SmithTR , SunshineA , StarkSR , LittlefieldDE , SpruillSE , AlexanderWJ . Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache2005;45(8):983-91. [DOI: 10.1111/j.1526-4610.2005.05178.x]">Smith 2005</a>), compared with sumatriptan alone (1925 participants) or naproxen alone (1944 participants), when pain was moderate or severe. </p> <p> <ul id="CD008541-list-0018"> <li> <p>The proportion of participants with 24‐hour sustained headache relief with sumatriptan plus naproxen 50 to 85/500 mg was 46% (447/976; range 44% to 48%). </p> </li> <li> <p>The proportion of participants with 24‐hour sustained headache relief with sumatriptan alone was 33% (314/949; range 29% to 35%). </p> </li> <li> <p>The proportion of participants with 24‐hour sustained headache relief with naproxen alone was 28% (271/968; range 25% to 30%). </p> </li> <li> <p>The relative benefit of the combination compared with sumatriptan alone was 1.4 (95% CI 1.2 to 1.6); the NNT was 7.9 (95% CI 5.9 to 12) (<a href="./references#CD008541-fig-0019" title="">Analysis 2.4</a>). </p> </li> <li> <p>The relative benefit of the combination compared with naproxen alone was 1.6 (95% CI 1.5 to 1.9); the NNT was 5.6 (95% CI 4.5 to 7.4) (<a href="./references#CD008541-fig-0027" title="">Analysis 3.4</a>). </p> </li> </ul> </p> <p>The combination was significantly better than either sumatriptan or naproxen alone.</p> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Summary of results: Pain‐free and headache relief</b> </p> </td> </tr> <tr> <td align="" class="headercell" colspan="1" rowspan="1" valign=""></td> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Baseline pain</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Studies</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Attacks</b> </p> <p><b>treated</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Treatment</b> </p> <p><b>(%)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo or comparator</b> </p> <p><b>(%)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk ratio (95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>NNT</b> </p> <p><b>(95% CI)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>Pain‐free at 2 h</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="middle"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan plus naproxen 85/500 mg vs placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mild</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3395</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.8 (2.4 to 3.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1 (2.9 to 3.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan plus naproxen 50‐85/500 mg vs placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ mod</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2596</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.7 (3.0 to 4.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.9 (4.3 to 5.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan plus naproxen 85/500 mg vs placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ mod</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2105</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.3 (2.6 to 4.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.4 (4.6 to 6.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan plus naproxen 50‐85/500 mg vs sumatriptan 50‐85 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ mod</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1925</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4 (1.2 to 1.7)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (7.4 to 18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan plus naproxen 50‐85/500 mg vs naproxen 500 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ mod</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1944</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.0 (1.7 to 2.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.1 (5.0 to 7.9)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Headache relief at 2 h</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan plus naproxen 50‐85/500 mg vs placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ mod</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2596</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.2 (2.0 to 2.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.2 (2.9 to 3.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan plus naproxen 85/500 mg vs placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ mod</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2105</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1 (1.9 to 2.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.4 (3.0 to 3.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan plus naproxen 50‐85/500 mg vs sumatriptan 50‐85 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ mod</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1925</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2 (1.1 to 1.3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.8 (6.8 to 17)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan plus naproxen 50‐85/500 mg vs naproxen 500 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ mod</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1944</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4 (1.3 to 1.5)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.5 (4.4 to 7.2)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sustained pain‐free during the 24 h post dose</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan plus naproxen 85/500 mg vs placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mild</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3396</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.0 (2.6 to 3.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.1 (3.7 to 4.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan plus naproxen 50‐85/500 mg vs placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ mod</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2596</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.4 (2.7 to 4.4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.0 (5.9 to 8.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan plus naproxen 85/500 mg vs placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ mod</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2005</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1 (2.4 to 4.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.7 (6.4 to 9.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan plus naproxen 50‐85/500 mg vs sumatriptan 50‐85 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ mod</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1925</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7 (1.4 to 2.1)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (7.4 to 15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan plus naproxen 50‐85/500 mg vs naproxen 500 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ mod</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1944</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3 (1.8 to 2.8)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.4 (6.0 to 9.9)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sustained headache relief during the 24 h post dose</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan plus naproxen 50‐85/500 mg vs placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ mod</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2596</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6 (2.3 to 3.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.8 (3.4 to 4.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan plus naproxen 85/500 mg vs placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ mod</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2107</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6 (2.2 to 3.0)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.9 (3.4 to 4.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan plus naproxen 50‐85/500 mg vs sumatriptan 50‐85 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ mod</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1925</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4 (1.2 to 1.6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.9 (5.9 to 12)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan plus naproxen 50‐85/500 mg vs naproxen 500 mg</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ mod</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1944</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.6 (1.5 to 1.9)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.6 (4.5 to 7.4)</p> </td> </tr> </tbody> </table> </div> </p> </section> </section> <section id="CD008541-sec-0067"> <h4 class="title">Subgroup analysis of primary outcomes</h4> <p>Subgroup analysis according to the timing of initial medication (early while pain was mild, or once pain was moderate or severe) has been considered in the main analysis above, with early treatment giving better efficacy for pain‐free responses at two hours and during the 24 hours post dose. Similarly, dose has been considered in the main analysis: all studies used sumatriptan 85 mg combined with naproxen 500 mg except <a href="./references#CD008541-bbs2-0012" title="SmithTR , SunshineA , StarkSR , LittlefieldDE , SpruillSE , AlexanderWJ . Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache2005;45(8):983-91. [DOI: 10.1111/j.1526-4610.2005.05178.x]">Smith 2005</a>, which used sumatriptan 50 mg combined with naproxen 500 mg. Inclusion of the lower dose did not significantly change the results. </p> <p>All studies used the oral route of administration, and none used multiple dosing strategies.</p> </section> <section id="CD008541-sec-0068"> <h4 class="title">Sensitivity analysis of primary outcomes</h4> <p>All studies scored at least 3/5 for methodological quality on the Oxford Quality Scale, and no studies provided separate data for participants with or without aura so no sensitivity analysis could be carried out for these criteria. There was no evidence that results from the studies reporting combined data from both phases of the cross‐over differed from those reporting first‐phase‐only data (<a href="./references#CD008541-bbs2-0008" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 1</a>; <a href="./references#CD008541-bbs2-0009" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 2</a>; <a href="./references#CD008541-bbs2-0013" title="A randomized, double-blind, double-dummy, placebo-controlled, crossover study to evaluate the efficacy of TREXIMET (sumatriptan + naproxen sodium) versus Butalbital-Containing Combination Medications (BCM) for the acute treatment of migraine when administered during the moderate-severe pain phase of the migraine (pooled data), 2010. download.gsk-clinicalstudyregister.com/files/21144.pdf (accessed 23 September 2013). DerosierF , SheftellF , SilbersteinS , CadyR , RuoffG , KrishenA , et al. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache2012;52(4):530-43. [DOI: 10.1111/j.1526-4610.2011.02039.x]">TRX109011/13</a>). There was also no evidence that results for the study that enrolled only participants who had previously had a poor response to triptans with a short half‐life (including sumatriptan) differed from those who enrolled participants who had previously tolerated treatment with a triptan or had no contraindications, or both (<a href="./references#CD008541-bbs2-0008" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 1</a>; <a href="./references#CD008541-bbs2-0009" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 2</a>). </p> <p>Two studies included only participants with menstrual migraine (<a href="./references#CD008541-bbs2-0006" title="CadyRK , DiamondML , DiamondMP , BallardJE , LenerME , DornerDP , et al. Sumatriptan - naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache2011;51(5):664-73. [DOI: 10.1111/j.1526-4610.2011.01894.x]MannixLK , MartinVT , CadyRK , DiamondML , LenerSE , WhiteJD , et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Journal of Obstetrics and Gynecology2009;114(1):106-13. [DOI: 10.1097/AOG.0b013e3181a98e4d]MartinVT , BallardJ , DiamondMP , MannixLK , DerosierFJ , LenerSE , et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Journal of Women's Health2014;23(5):389-96. [DOI: 10.1089/jwh.2013.4577]">Mannix 2009 Study 1;</a><a href="./references#CD008541-bbs2-0007" title="CadyRK , DiamondML , DiamondMP , BallardJE , LenerME , DornerDP , et al. Sumatriptan - naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache2011;51(5):664-73. [DOI: 10.1111/j.1526-4610.2011.01894.x]MannixLK , MartinVT , CadyRK , DiamondML , LenerSE , WhiteJD , et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Journal of Obstetrics and Gynecology2009;114(1):106-13. [DOI: 10.1097/AOG.0b013e3181a98e4d]MartinVT , BallardJ , DiamondMP , MannixLK , DerosierFJ , LenerSE , et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Journal of Women's Health2014;23(5):389-96. [DOI: 10.1089/jwh.2013.4577]">Mannix 2009 Study 2</a>). Results for these studies were similar to other studies treating mild pain for the outcomes of pain‐free at two hours (<a href="#CD008541-fig-0003">Figure 3</a>), and sustained pain‐free during the 24 hours post dose (<a href="./references#CD008541-fig-0010" title="">Analysis 1.3</a>); removing the menstrual migraine studies from the analyses made no difference. </p> <p>The three cross‐over studies that did not report first‐period data separately, but only all‐period data (<a href="./references#CD008541-bbs2-0008" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 1</a>; <a href="./references#CD008541-bbs2-0009" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 2</a>; <a href="./references#CD008541-bbs2-0013" title="A randomized, double-blind, double-dummy, placebo-controlled, crossover study to evaluate the efficacy of TREXIMET (sumatriptan + naproxen sodium) versus Butalbital-Containing Combination Medications (BCM) for the acute treatment of migraine when administered during the moderate-severe pain phase of the migraine (pooled data), 2010. download.gsk-clinicalstudyregister.com/files/21144.pdf (accessed 23 September 2013). DerosierF , SheftellF , SilbersteinS , CadyR , RuoffG , KrishenA , et al. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache2012;52(4):530-43. [DOI: 10.1111/j.1526-4610.2011.02039.x]">TRX109011/13</a>), gave results that were indistinguishable from those from other studies (<a href="#CD008541-fig-0003">Figure 3</a>; <a href="#CD008541-fig-0005">Figure 5</a>; <a href="./references#CD008541-fig-0010" title="">Analysis 1.3</a>; <a href="./references#CD008541-fig-0011" title="">Analysis 1.4</a>). </p> </section> <section id="CD008541-sec-0069"> <h4 class="title">Sumatriptan plus naproxen versus active controls</h4> <p>One study compared the combination with a butalbital‐containing active comparator (<a href="./references#CD008541-bbs2-0013" title="A randomized, double-blind, double-dummy, placebo-controlled, crossover study to evaluate the efficacy of TREXIMET (sumatriptan + naproxen sodium) versus Butalbital-Containing Combination Medications (BCM) for the acute treatment of migraine when administered during the moderate-severe pain phase of the migraine (pooled data), 2010. download.gsk-clinicalstudyregister.com/files/21144.pdf (accessed 23 September 2013). DerosierF , SheftellF , SilbersteinS , CadyR , RuoffG , KrishenA , et al. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache2012;52(4):530-43. [DOI: 10.1111/j.1526-4610.2011.02039.x]">TRX109011/13</a>); there were insufficient data for a head‐to‐head analysis of the two treatments from this single trial. Sumatriptan plus naproxen was reported to be statistically superior to the butalbital combination for pain‐free response at all time points between 2 and 48 hours. </p> </section> <section id="CD008541-sec-0070"> <h4 class="title">Adverse events</h4> <section id="CD008541-sec-0071"> <h5 class="title">Any adverse event</h5> <p>All studies reported some information about participants who experienced one or more adverse events, but the reporting was inconsistent. <a href="./references#CD008541-bbs2-0006" title="CadyRK , DiamondML , DiamondMP , BallardJE , LenerME , DornerDP , et al. Sumatriptan - naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache2011;51(5):664-73. [DOI: 10.1111/j.1526-4610.2011.01894.x]MannixLK , MartinVT , CadyRK , DiamondML , LenerSE , WhiteJD , et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Journal of Obstetrics and Gynecology2009;114(1):106-13. [DOI: 10.1097/AOG.0b013e3181a98e4d]MartinVT , BallardJ , DiamondMP , MannixLK , DerosierFJ , LenerSE , et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Journal of Women's Health2014;23(5):389-96. [DOI: 10.1089/jwh.2013.4577]">Mannix 2009 Study 1</a> and <a href="./references#CD008541-bbs2-0007" title="CadyRK , DiamondML , DiamondMP , BallardJE , LenerME , DornerDP , et al. Sumatriptan - naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache2011;51(5):664-73. [DOI: 10.1111/j.1526-4610.2011.01894.x]MannixLK , MartinVT , CadyRK , DiamondML , LenerSE , WhiteJD , et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Journal of Obstetrics and Gynecology2009;114(1):106-13. [DOI: 10.1097/AOG.0b013e3181a98e4d]MartinVT , BallardJ , DiamondMP , MannixLK , DerosierFJ , LenerSE , et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Journal of Women's Health2014;23(5):389-96. [DOI: 10.1089/jwh.2013.4577]">Mannix 2009 Study 2</a> reported only that less than a certain percentage had experienced drug‐related adverse events. Cross‐over studies (<a href="./references#CD008541-bbs2-0008" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 1</a> and <a href="./references#CD008541-bbs2-0009" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 2</a>) reported the percentage with adverse events for each treatment; the reported safety populations for the two studies were 144 and 139 participants, respectively; for the analysis, we have assumed that all took both study medications. The other studies reported participants with adverse events in each treatment arm, but <a href="./references#CD008541-bbs2-0001" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 1</a>, <a href="./references#CD008541-bbs2-0002" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 2</a>, and <a href="./references#CD008541-bbs2-0012" title="SmithTR , SunshineA , StarkSR , LittlefieldDE , SpruillSE , AlexanderWJ . Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache2005;45(8):983-91. [DOI: 10.1111/j.1526-4610.2005.05178.x]">Smith 2005</a> reported events occurring within 24 hours of taking study medication, while <a href="./references#CD008541-bbs2-0004" title="LandySH , CadyRK , NelsenA , WhiteJ , RunkenMC . Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination. Headache2014;54(4):640-54. [DOI: 10.1111/head.12214]LiptonRB , DodickDW , AdelmanJU , KanieckiRG , LenerSE , WhiteJD , et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia2009;29(8):826-36. [DOI: 10.1111/j.1468-2982.2008.01806.x]">Lipton 2009 Study 1</a>, <a href="./references#CD008541-bbs2-0005" title="LandySH , CadyRK , NelsenA , WhiteJ , RunkenMC . Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination. Headache2014;54(4):640-54. [DOI: 10.1111/head.12214]LiptonRB , DodickDW , AdelmanJU , KanieckiRG , LenerSE , WhiteJD , et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia2009;29(8):826-36. [DOI: 10.1111/j.1468-2982.2008.01806.x]">Lipton 2009 Study 2</a>, and <a href="./references#CD008541-bbs2-0013" title="A randomized, double-blind, double-dummy, placebo-controlled, crossover study to evaluate the efficacy of TREXIMET (sumatriptan + naproxen sodium) versus Butalbital-Containing Combination Medications (BCM) for the acute treatment of migraine when administered during the moderate-severe pain phase of the migraine (pooled data), 2010. download.gsk-clinicalstudyregister.com/files/21144.pdf (accessed 23 September 2013). DerosierF , SheftellF , SilbersteinS , CadyR , RuoffG , KrishenA , et al. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache2012;52(4):530-43. [DOI: 10.1111/j.1526-4610.2011.02039.x]">TRX109011/13</a> reported over 72 hours, and <a href="./references#CD008541-bbs2-0010" title="SilbersteinSD , MannixLK , GoldsteinJ , CouchJR , ByrdSC , AmesMH , et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology2008;71(2):114-21. [DOI: 10.1212/01.wnl.0000316800.22949.20]TaylorFR , HeiringJO , MessinaE , Braverman-PanzaJ , AmesMH , ByrdSC , et al. Sumatriptan/naproxen sodium as early intervention for migraine: effects on functional ability, productivity, and satisfaction in 2 randomized controlled trials. Journal of Clinical Outcomes Management2007;14(4):195-204. ">Silberstein 2008 Study 1</a> and <a href="./references#CD008541-bbs2-0011" title="SilbersteinSD , MannixLK , GoldsteinJ , CouchJR , ByrdSC , AmesMH , et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology2008;71(2):114-21. [DOI: 10.1212/01.wnl.0000316800.22949.20]TaylorFR , HeiringJO , MessinaE , Braverman-PanzaJ , AmesMH , ByrdSC , et al. Sumatriptan/naproxen sodium as early intervention for migraine: effects on functional ability, productivity, and satisfaction in 2 randomized controlled trials. Journal of Clinical Outcomes Management2007;14(4):195-204. ">Silberstein 2008 Study 2</a> up to one week. Since there was no obvious relationship between numbers of participants with adverse events and the time over which the data were collected, we have combined data from different time periods for analysis. </p> </section> <section id="CD008541-sec-0072"> <h5 class="title">Sumatriptan plus naproxen 85/500 mg versus placebo</h5> <p>Six studies (2823 attacks) treating when pain was still mild (<a href="./references#CD008541-bbs2-0004" title="LandySH , CadyRK , NelsenA , WhiteJ , RunkenMC . Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination. Headache2014;54(4):640-54. [DOI: 10.1111/head.12214]LiptonRB , DodickDW , AdelmanJU , KanieckiRG , LenerSE , WhiteJD , et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia2009;29(8):826-36. [DOI: 10.1111/j.1468-2982.2008.01806.x]">Lipton 2009 Study 1</a>; <a href="./references#CD008541-bbs2-0005" title="LandySH , CadyRK , NelsenA , WhiteJ , RunkenMC . Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination. Headache2014;54(4):640-54. [DOI: 10.1111/head.12214]LiptonRB , DodickDW , AdelmanJU , KanieckiRG , LenerSE , WhiteJD , et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia2009;29(8):826-36. [DOI: 10.1111/j.1468-2982.2008.01806.x]">Lipton 2009 Study 2</a>; <a href="./references#CD008541-bbs2-0008" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 1</a>; <a href="./references#CD008541-bbs2-0009" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 2</a>; <a href="./references#CD008541-bbs2-0010" title="SilbersteinSD , MannixLK , GoldsteinJ , CouchJR , ByrdSC , AmesMH , et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology2008;71(2):114-21. [DOI: 10.1212/01.wnl.0000316800.22949.20]TaylorFR , HeiringJO , MessinaE , Braverman-PanzaJ , AmesMH , ByrdSC , et al. Sumatriptan/naproxen sodium as early intervention for migraine: effects on functional ability, productivity, and satisfaction in 2 randomized controlled trials. Journal of Clinical Outcomes Management2007;14(4):195-204. ">Silberstein 2008 Study 1</a>; <a href="./references#CD008541-bbs2-0011" title="SilbersteinSD , MannixLK , GoldsteinJ , CouchJR , ByrdSC , AmesMH , et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology2008;71(2):114-21. [DOI: 10.1212/01.wnl.0000316800.22949.20]TaylorFR , HeiringJO , MessinaE , Braverman-PanzaJ , AmesMH , ByrdSC , et al. Sumatriptan/naproxen sodium as early intervention for migraine: effects on functional ability, productivity, and satisfaction in 2 randomized controlled trials. Journal of Clinical Outcomes Management2007;14(4):195-204. ">Silberstein 2008 Study 2</a>), and four (2793 attacks) treating when pain was moderate or severe (<a href="./references#CD008541-bbs2-0001" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 1</a>; <a href="./references#CD008541-bbs2-0002" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 2</a>; <a href="./references#CD008541-bbs2-0012" title="SmithTR , SunshineA , StarkSR , LittlefieldDE , SpruillSE , AlexanderWJ . Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache2005;45(8):983-91. [DOI: 10.1111/j.1526-4610.2005.05178.x]">Smith 2005</a>; <a href="./references#CD008541-bbs2-0013" title="A randomized, double-blind, double-dummy, placebo-controlled, crossover study to evaluate the efficacy of TREXIMET (sumatriptan + naproxen sodium) versus Butalbital-Containing Combination Medications (BCM) for the acute treatment of migraine when administered during the moderate-severe pain phase of the migraine (pooled data), 2010. download.gsk-clinicalstudyregister.com/files/21144.pdf (accessed 23 September 2013). DerosierF , SheftellF , SilbersteinS , CadyR , RuoffG , KrishenA , et al. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache2012;52(4):530-43. [DOI: 10.1111/j.1526-4610.2011.02039.x]">TRX109011/13</a>), provided data for analysis. </p> <section id="CD008541-sec-0073"> <h6 class="title">Mild baseline pain</h6> <p> <ul id="CD008541-list-0019"> <li> <p>The proportion of attacks with one or more adverse events with sumatriptan plus naproxen 85/500 mg was 14% (241/1749; range 9.4% to 19%). </p> </li> <li> <p>The proportion of attacks with one or more adverse events with placebo was 8.2% (88/1074; range 4.2% to 14%). </p> </li> <li> <p>The RR of treatment compared with placebo was 1.5 (95% CI 1.2 to 1.9) (<a href="./references#CD008541-fig-0012" title="">Analysis 1.5</a>); the NNH was 18 (95% CI 13 to 30). </p> </li> </ul> </p> </section> <section id="CD008541-sec-0074"> <h6 class="title">Moderate to severe baseline pain</h6> <p> <ul id="CD008541-list-0020"> <li> <p>The proportion of attacks with one or more adverse events with sumatriptan plus naproxen 85/500 mg was 21% (291/1394; range 8.9% to 27%). </p> </li> <li> <p>The proportion of attacks with one or more adverse events with placebo was 11% (148/1399; range 6.9% to 15%). </p> </li> <li> <p>The RR of treatment compared with placebo was 2.0 (95% CI 1.6 to 2.4) (<a href="./references#CD008541-fig-0012" title="">Analysis 1.5</a>); the NNH was 9.7 (95% CI 7.7 to 13). </p> </li> </ul> </p> <p>There was a significant difference in the number of attacks in which one or more adverse events was experienced between those treated early when pain was still mild, and those treated when pain was moderate or severe (z = 2.6167, P value = 0.0088). </p> </section> </section> <section id="CD008541-sec-0075"> <h5 class="title">Sumatriptan plus naproxen 50 to 85/500 mg versus sumatriptan alone or naproxen alone</h5> <p>Three studies provided data comparing sumatriptan/naproxen versus both sumatriptan (1952 participants) and naproxen (1970 participants) alone (<a href="./references#CD008541-bbs2-0001" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 1</a>; <a href="./references#CD008541-bbs2-0002" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 2</a>; <a href="./references#CD008541-bbs2-0012" title="SmithTR , SunshineA , StarkSR , LittlefieldDE , SpruillSE , AlexanderWJ . Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache2005;45(8):983-91. [DOI: 10.1111/j.1526-4610.2005.05178.x]">Smith 2005</a>). Medication was taken when PI was moderate or severe. </p> <p> <ul id="CD008541-list-0021"> <li> <p>The proportion of participants experiencing adverse events with sumatriptan/naproxen 85/500 mg was 26% (255/988; range 23% to 27%). </p> </li> <li> <p>The proportion of participants experiencing adverse events with sumatriptan 85 mg alone was 26% (249/964; range 24% to 28%). </p> </li> <li> <p>The proportion of participants experiencing adverse events with naproxen 500 mg alone was 15% (143/982; range 13% to 17%). </p> </li> <li> <p>The RR of the combination compared with sumatriptan alone was 1.0 (95% CI 0.9 to 1.2) (<a href="./references#CD008541-fig-0020" title="">Analysis 2.5</a>); the NNH was not calculated. </p> </li> <li> <p>The RR of the combination compared with naproxen alone was 1.8 (95% CI 1.5 to 2.1); the NNH was 8.9 (95% CI 6.8 to 13) (<a href="./references#CD008541-fig-0028" title="">Analysis 3.5</a>). </p> </li> </ul> </p> <p>There was no difference in these studies between the combination and sumatriptan alone, but fewer participants experienced adverse events with naproxen alone. </p> </section> <section id="CD008541-sec-0076"> <h5 class="title">Specific adverse events</h5> <p>Dizziness, paraesthesia, somnolence, nausea, dyspepsia, dry mouth, and chest discomfort were the most commonly reported adverse events, and were somewhat more common with combination therapy than monotherapy, and more common with active therapies than placebo. The incidence of any specific event in individual studies was low (less than 4%) and not consistently reported across studies, so numbers of reported events were small and no analysis was possible. </p> </section> <section id="CD008541-sec-0077"> <h5 class="title">Serious adverse events</h5> <p>One participant, who had several cardiovascular risk factors, experienced heart palpitations and was admitted to hospital after receiving sumatriptan 85 mg; the event was judged probably related to study medication (<a href="./references#CD008541-bbs2-0001" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 1</a>). Seven participants in <a href="./references#CD008541-bbs2-0004" title="LandySH , CadyRK , NelsenA , WhiteJ , RunkenMC . Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination. Headache2014;54(4):640-54. [DOI: 10.1111/head.12214]LiptonRB , DodickDW , AdelmanJU , KanieckiRG , LenerSE , WhiteJD , et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia2009;29(8):826-36. [DOI: 10.1111/j.1468-2982.2008.01806.x]">Lipton 2009 Study 1</a> and <a href="./references#CD008541-bbs2-0005" title="LandySH , CadyRK , NelsenA , WhiteJ , RunkenMC . Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination. Headache2014;54(4):640-54. [DOI: 10.1111/head.12214]LiptonRB , DodickDW , AdelmanJU , KanieckiRG , LenerSE , WhiteJD , et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia2009;29(8):826-36. [DOI: 10.1111/j.1468-2982.2008.01806.x]">Lipton 2009 Study 2</a> experienced serious adverse events, none of which were judged related to study medication or occurred within 72 hours of receiving study medication. A further five serious adverse events occurred in <a href="./references#CD008541-bbs2-0013" title="A randomized, double-blind, double-dummy, placebo-controlled, crossover study to evaluate the efficacy of TREXIMET (sumatriptan + naproxen sodium) versus Butalbital-Containing Combination Medications (BCM) for the acute treatment of migraine when administered during the moderate-severe pain phase of the migraine (pooled data), 2010. download.gsk-clinicalstudyregister.com/files/21144.pdf (accessed 23 September 2013). DerosierF , SheftellF , SilbersteinS , CadyR , RuoffG , KrishenA , et al. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache2012;52(4):530-43. [DOI: 10.1111/j.1526-4610.2011.02039.x]">TRX109011/13</a>, which were also judged unrelated to the study medication. </p> </section> </section> <section id="CD008541-sec-0078"> <h4 class="title">Withdrawals</h4> <p>Six studies reported that there were no adverse event withdrawals (<a href="./references#CD008541-bbs2-0001" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 1</a>; <a href="./references#CD008541-bbs2-0006" title="CadyRK , DiamondML , DiamondMP , BallardJE , LenerME , DornerDP , et al. Sumatriptan - naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache2011;51(5):664-73. [DOI: 10.1111/j.1526-4610.2011.01894.x]MannixLK , MartinVT , CadyRK , DiamondML , LenerSE , WhiteJD , et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Journal of Obstetrics and Gynecology2009;114(1):106-13. [DOI: 10.1097/AOG.0b013e3181a98e4d]MartinVT , BallardJ , DiamondMP , MannixLK , DerosierFJ , LenerSE , et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Journal of Women's Health2014;23(5):389-96. [DOI: 10.1089/jwh.2013.4577]">Mannix 2009 Study 1</a>; <a href="./references#CD008541-bbs2-0007" title="CadyRK , DiamondML , DiamondMP , BallardJE , LenerME , DornerDP , et al. Sumatriptan - naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache2011;51(5):664-73. [DOI: 10.1111/j.1526-4610.2011.01894.x]MannixLK , MartinVT , CadyRK , DiamondML , LenerSE , WhiteJD , et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Journal of Obstetrics and Gynecology2009;114(1):106-13. [DOI: 10.1097/AOG.0b013e3181a98e4d]MartinVT , BallardJ , DiamondMP , MannixLK , DerosierFJ , LenerSE , et al. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. Journal of Women's Health2014;23(5):389-96. [DOI: 10.1089/jwh.2013.4577]">Mannix 2009 Study 2</a>; <a href="./references#CD008541-bbs2-0009" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 2</a>; <a href="./references#CD008541-bbs2-0010" title="SilbersteinSD , MannixLK , GoldsteinJ , CouchJR , ByrdSC , AmesMH , et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology2008;71(2):114-21. [DOI: 10.1212/01.wnl.0000316800.22949.20]TaylorFR , HeiringJO , MessinaE , Braverman-PanzaJ , AmesMH , ByrdSC , et al. Sumatriptan/naproxen sodium as early intervention for migraine: effects on functional ability, productivity, and satisfaction in 2 randomized controlled trials. Journal of Clinical Outcomes Management2007;14(4):195-204. ">Silberstein 2008 Study 1</a>; <a href="./references#CD008541-bbs2-0011" title="SilbersteinSD , MannixLK , GoldsteinJ , CouchJR , ByrdSC , AmesMH , et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology2008;71(2):114-21. [DOI: 10.1212/01.wnl.0000316800.22949.20]TaylorFR , HeiringJO , MessinaE , Braverman-PanzaJ , AmesMH , ByrdSC , et al. Sumatriptan/naproxen sodium as early intervention for migraine: effects on functional ability, productivity, and satisfaction in 2 randomized controlled trials. Journal of Clinical Outcomes Management2007;14(4):195-204. ">Silberstein 2008 Study 2</a>), and another did not mention any adverse event withdrawals (<a href="./references#CD008541-bbs2-0012" title="SmithTR , SunshineA , StarkSR , LittlefieldDE , SpruillSE , AlexanderWJ . Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache2005;45(8):983-91. [DOI: 10.1111/j.1526-4610.2005.05178.x]">Smith 2005</a>). There was one withdrawal (palpitations following sumatriptan 85 mg) in <a href="./references#CD008541-bbs2-0001" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 1</a>; eight withdrawals (all following combination treatment, three with mild or moderate chest discomfort) in <a href="./references#CD008541-bbs2-0004" title="LandySH , CadyRK , NelsenA , WhiteJ , RunkenMC . Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination. Headache2014;54(4):640-54. [DOI: 10.1111/head.12214]LiptonRB , DodickDW , AdelmanJU , KanieckiRG , LenerSE , WhiteJD , et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia2009;29(8):826-36. [DOI: 10.1111/j.1468-2982.2008.01806.x]">Lipton 2009 Study 1</a>; six withdrawals (three with mild or moderate chest discomfort and three with nausea following combination treatment, and one with nausea following placebo) in <a href="./references#CD008541-bbs2-0005" title="LandySH , CadyRK , NelsenA , WhiteJ , RunkenMC . Consistency of return to normal function, productivity, and satisfaction following migraine attacks treated with sumatriptan/naproxen sodium combination. Headache2014;54(4):640-54. [DOI: 10.1111/head.12214]LiptonRB , DodickDW , AdelmanJU , KanieckiRG , LenerSE , WhiteJD , et al. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia2009;29(8):826-36. [DOI: 10.1111/j.1468-2982.2008.01806.x]">Lipton 2009 Study 2</a>; and one (muscle tightness, heaviness, anxiety, and nervousness following placebo) in <a href="./references#CD008541-bbs2-0008" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 1</a>. Four subjects were withdrawn in <a href="./references#CD008541-bbs2-0013" title="A randomized, double-blind, double-dummy, placebo-controlled, crossover study to evaluate the efficacy of TREXIMET (sumatriptan + naproxen sodium) versus Butalbital-Containing Combination Medications (BCM) for the acute treatment of migraine when administered during the moderate-severe pain phase of the migraine (pooled data), 2010. download.gsk-clinicalstudyregister.com/files/21144.pdf (accessed 23 September 2013). DerosierF , SheftellF , SilbersteinS , CadyR , RuoffG , KrishenA , et al. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache2012;52(4):530-43. [DOI: 10.1111/j.1526-4610.2011.02039.x]">TRX109011/13</a>; two due to pregnancy, one due to use of prohibited medication, and one due to a new diagnosis of breast cancer. </p> <p>Participants who took rescue medication were classified as withdrawals due to lack of efficacy, and details are reported under 'Use of rescue medication' (<a href="./appendices#CD008541-sec-0106">Appendix 8</a>). </p> <p>Exclusion of participants from analyses after randomisation were mostly due to protocol violations or failing to take the medication (no qualifying headache, or cross‐over not completed), and were generally well reported. Numbers of participants lost to follow‐up, or withdrawing due for unspecified reasons were small and unlikely to influence results. </p> </section> <section id="CD008541-sec-0079"> <h4 class="title">Other outcomes</h4> <p>Results for use of rescue medication, relief of headache‐associated symptoms, and relief of functional disability are in <a href="./appendices#CD008541-sec-0106">Appendix 8</a>. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008541-sec-0080" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008541-sec-0080"></div> <section id="CD008541-sec-0081"> <h3 class="title" id="CD008541-sec-0081">Summary of main results</h3> <p>This updated review included 13 randomised, double‐blind, placebo‐controlled studies, of which 12 contributed to analyses. For the primary outcome of pain‐free at two hours, data were available for analysis for 3318 headaches treated with sumatriptan plus naproxen and 2673 treated with placebo. Of these, 2025 headaches were treated when the pain was of mild severity and 1293 when the pain was moderate or severe. This allowed analysis of the effect of different dosing regimens on the primary outcomes. Most studies used a standard combination tablet of sumatriptan 85 mg and naproxen 500 mg, but one used two separate tablets of sumatriptan 50 mg and naproxen 500 mg. Two studies included active comparators, which allowed analysis of the combination formulation versus monotherapy, for example, sumatriptan or naproxen. One study included a different active comparator, but there were insufficient data for analysis (<a href="./references#CD008541-bbs2-0013" title="A randomized, double-blind, double-dummy, placebo-controlled, crossover study to evaluate the efficacy of TREXIMET (sumatriptan + naproxen sodium) versus Butalbital-Containing Combination Medications (BCM) for the acute treatment of migraine when administered during the moderate-severe pain phase of the migraine (pooled data), 2010. download.gsk-clinicalstudyregister.com/files/21144.pdf (accessed 23 September 2013). DerosierF , SheftellF , SilbersteinS , CadyR , RuoffG , KrishenA , et al. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache2012;52(4):530-43. [DOI: 10.1111/j.1526-4610.2011.02039.x]">TRX109011/13</a>). </p> <p>For the IHS preferred outcome of pain‐free at two hours, the combination formulation was better than placebo both when pain was mild at baseline and when it was moderate to severe. NNTs were 3.1 and 4.9, with 50% and 28% of people being pain‐free with mild or moderate to severe pain, respectively (high quality evidence). A greater response was seen when headaches were mild and this result was statistically significant (P value &lt; 0.0001). For headache relief at two hours (analysis possible only for headaches with initial intensity of moderate or severe), the combination was better than placebo. The NNT was 3.2, with 58% of participants responding compared with 27% with placebo (high quality evidence). </p> <p>For the IHS preferred outcome of sustained pain‐free during the 24 hours post dose, the combination formulation was better than placebo both when pain was mild at baseline and when it was moderate to severe. NNTs were 4.1 and 7.0, with 37% and 20% of people being pain free with the combination, compared with 12% and 6% with placebo, for mild and moderate to severe pain, respectively (high and moderate quality evidence). A greater response was seen when headaches were mild and this result was statistically significant (P value &lt; 0.0008). For sustained headache relief during the 24 hours post dose, combination was better than placebo, with an NNT of 3.8 and 43% of participants responding compared with 16% with placebo (high quality evidence). Modest success rates for levels of PR considered useful by patients is the rule with different analgesics across many acute and chronic pain conditions (<a href="./references#CD008541-bbs2-0058" title="MooreA , DerryS , EcclestonC , KalsoE . Expect analgesic failure; pursue analgesic success. BMJ2013;346:f2690. [DOI: 10.1136/bmj.f2690]">Moore 2013</a>). </p> <p>One study did not contribute to analyses because of uncertainty about the denominator used to calculate the reported response rates (<a href="./references#CD008541-bbs2-0003" title="CalhounAH , FordS . Double-blind, placebo-controlled, crossover study of early-intervention with sumatriptan 85/naproxen sodium 500 in (truly) episodic migraine: what's neck pain got to do with it?Postgraduate Medicine2014;126(2):86-90. [DOI: 10.3810/pgm.2014.03.2743]">Calhoun 2014</a>). This study recruited a slightly different population, requiring that participants experienced fewer than 8 migraine headaches per month or fewer than 15 days per month with either headache or neck pain in any of the 3 months before screening. The authors believe that neck pain is integrally related to migraine, and that by ignoring it, studies recruit people who are not "truly episodic migraineurs". Their results suggest somewhat higher response rates in both sumatriptan plus naproxen and placebo treatment arms for pain‐free at two hours, and for 24‐hour sustained pain freedom. They also report a more rapid response than seen in earlier studies (5% pain‐free at 15 minutes with sumatriptan plus naproxen, 0% with placebo; 43 participants). Making various assumptions about the denominator to allow inclusion of this study in the analysis did not significantly change the results. This was unsurprising because of the small size of the study. The authors' hypothesis that this population of migraineurs achieve better response rates remains to be tested in larger studies. </p> <p>In all efficacy analyses, combination treatment was superior to monotherapy with either sumatriptan or naproxen alone. The use of separate tablets using sumatriptan in a lower dose (50 mg versus 85 mg) did not affect any results in a meaningful way. </p> <p>No analysis was possible for times shorter than two hours. Overall, 58% of participants treated with combination experienced headache relief at two hours, and just under 43% sustained relief for 24 hours. Half of the participants were pain free at two hours when treated early (mild pain), but only 28% when treated when pain was moderate or severe. For sustained pain‐free during the 24 hours post dose the percentages were lower, at 37% for mild pain and 20% for moderate or severe pain. </p> <p>There was a significant difference in the number of participants experiencing one or more adverse events between those treating early when pain was still mild (NNH 18) and those treating when pain was moderate or severe (NNH 9.7) (moderate quality evidence). Most adverse events were described as mild or moderate, and transient. The incidence of any specific adverse event was low (&lt; 4%) and serious adverse events and adverse event withdrawals were uncommon. </p> <p>Additional analyses showed that combination was significantly better than placebo or either drug alone for relief of associated symptoms (nausea, photophobia, and phonophobia) and functional disability (<a href="./appendices#CD008541-sec-0106">Appendix 8</a>). </p> </section> <section id="CD008541-sec-0082"> <h3 class="title" id="CD008541-sec-0082">Overall completeness and applicability of evidence</h3> <p>Included participants all had a diagnosis of migraine headaches according to IHS criteria and the information for active comparators was sufficiently large to allow for comparisons with placebo and both sumatriptan and naproxen monotherapy in order to generate conclusions about relative efficacy and harm. Most participants were recruited from neurology outpatient departments, so may be more refractory to treatment than the general public as a whole, and were carefully screened and excluded if there was any contraindication to a study medication. Additionally, two studies specifically recruited participants who had not previously experienced relief with short‐acting triptans, including sumatriptan, and all studies excluded individuals who experience chronic migraine or very frequent migraines (more than six or eight attacks per month), so results may not be applicable to those with frequent attacks. These factors could lead to an underestimate of treatment effect. All studies included participants with or without aura, but none reported results for the two types separately. </p> <p>A study of sumatriptan plus naproxen in people with probable migraine (ie who satisfy all but one of the diagnostic criteria for migraine (<a href="./references#CD008541-bbs2-0041" title="Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia2004;24 Suppl 1:9-160. [DOI: 10.1111/j.1468-2982.2003.00824.x]">IHS 2004</a>)) found similar benefits, compared with placebo, to those found in people who satisfy the strict diagnostic criteria for migraine (<a href="./references#CD008541-bbs2-0019" title="Glazo Smith Kline study register. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and tolerability of TREXIMET (sumatriptan 85mg and naproxen sodium 500mg) for a single moderate or severe headache in adults diagnosed with probable migraine without aura. www.clinicaltrials.gov/ct2/show/NCT00387881 (accessed 23 September 2013). SilbersteinS , McDonaldSA , GoldsteinJ , AuroraS , LenerSE , WhiteJ , et al. Sumatriptan/naproxen sodium for the acute treatment of probable migraine without aura: a randomized study. Cephalalgia2014;34(4):268-79. [DOI: 10.1177/0333102413508242]">TRX107563</a> and Silberstein et al. 2014). This is important because probable migraine is common amongst people seeking treatment for headache. </p> <p>Individual studies are underpowered to determine differences between treatments for adverse events, and even pooling studies may not provide adequate numbers of events to demonstrate differences or allow confidence in the size of the effect. Single‐dose studies are certainly unlikely to reveal rare, but potentially serious, adverse events. In these studies, the number of participants experiencing any adverse event with active treatment was greater than with placebo. It is likely that adverse event data continued to be recorded after taking rescue medication, which may confound the results due to adverse events associated with the rescue medication itself. </p> </section> <section id="CD008541-sec-0083"> <h3 class="title" id="CD008541-sec-0083">Quality of the evidence</h3> <p>Included studies were of good methodological quality and validity. Some did not adequately describe the method of randomisation or allocation concealment, but this may reflect the limitation of space in published articles rather than any flaw in methodology. Migraine was diagnosed using standard, validated criteria, and outcomes measured were generally those recommended by the IHS as being of clinical relevance, although not all studies reported the primary outcomes we sought. </p> <p>We considered no studies to be at high risk of bias for any of the criteria evaluated, except for <a href="./references#CD008541-bbs2-0003" title="CalhounAH , FordS . Double-blind, placebo-controlled, crossover study of early-intervention with sumatriptan 85/naproxen sodium 500 in (truly) episodic migraine: what's neck pain got to do with it?Postgraduate Medicine2014;126(2):86-90. [DOI: 10.3810/pgm.2014.03.2743]">Calhoun 2014</a>, which had fewer than 50 participants per treatment arm, but did not contribute to any analyses. </p> <p>We judged the overall quality of the evidence as moderate to high for comparisons of sumatriptan plus naproxen with placebo, and moderate for comparisons of the combination with the individual components. Quality was downgraded because of the modest number of studies, and for some comparisons events, which meant that further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> </section> <section id="CD008541-sec-0084"> <h3 class="title" id="CD008541-sec-0084">Potential biases in the review process</h3> <p>One potential area of concern is the small numbers of events for some outcomes, particularly for specific adverse events. </p> <p>For three of the cross‐over studies (<a href="./references#CD008541-bbs2-0008" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 1</a>; <a href="./references#CD008541-bbs2-0009" title="MathewNT , LandyS , StarkS , TietjenGE , DerosierFJ , WhiteJ , et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache2009;49(7):971-82. [DOI: 10.1111/j.1526-4610.2009.01458.x]">Mathew 2009 Study 2</a>; <a href="./references#CD008541-bbs2-0013" title="A randomized, double-blind, double-dummy, placebo-controlled, crossover study to evaluate the efficacy of TREXIMET (sumatriptan + naproxen sodium) versus Butalbital-Containing Combination Medications (BCM) for the acute treatment of migraine when administered during the moderate-severe pain phase of the migraine (pooled data), 2010. download.gsk-clinicalstudyregister.com/files/21144.pdf (accessed 23 September 2013). DerosierF , SheftellF , SilbersteinS , CadyR , RuoffG , KrishenA , et al. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache2012;52(4):530-43. [DOI: 10.1111/j.1526-4610.2011.02039.x]">TRX109011/13</a>), we have used data from all phases. While this may introduce unknown biases (<a href="./references#CD008541-bbs2-0033" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , VailA . Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31(1):140-9. [DOI: 10.1093/ije/31.1.140]">Elbourne 2002</a>), the data from these studies was entirely consistent with data from all others for efficacy outcomes. </p> <p>We identified a large amount of data in comparisons with placebo. Approximately 2000 additional participants would have to have been involved in unpublished trials with zero treatment effect for the NNT for headache relief at two hours to increase above 6 (which we considered the limit of clinical utility in this situation) with the combination therapy (<a href="./references#CD008541-bbs2-0054" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA , editors(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-24. [ISBN: 978-0-931092-69-5]">Moore 2008</a>). This equates to five studies with over 400 participants in active and placebo treatment arms. Similarly, over 5000 additional participants would have to have been involved in unpublished trials with zero treatment effects for the NNT for pain‐free at two hours to increase above 8 (considered to be the limit of clinical utility in this situation), when baseline pain was mild, or almost 2000 when baseline pain was moderate or severe. It is unlikely that such a large amount of unidentified data exists, so publication bias is not a concern. </p> </section> <section id="CD008541-sec-0085"> <h3 class="title" id="CD008541-sec-0085">Agreements and disagreements with other studies or reviews</h3> <p>Naproxen for acute migraine is the subject of two systematic reviews (<a href="./references#CD008541-bbs2-0023" title="Bandolier. Naproxen for acute migraine, 2000. www.medicine.ox.ac.uk/bandolier/booth/Migraine/NapORacu.html (accessed 19 November 2015).">Bandolier 2000</a>; <a href="./references#CD008541-bbs2-0047" title="LawS , DerryS , MooreRA . Naproxen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD009455]">Law 2013b</a>). One Cochrane review provides information on oral sumatriptan alone (<a href="./references#CD008541-bbs2-0031" title="DerryCJ , DerryS , MooreRA . Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD008615.pub2]">Derry 2012</a>). NNT values for headache relief at two hours were: </p> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Drug and dose (mg)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>NNT for headache relief at 2 h</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Naproxen 500 mg vs placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan 50 mg vs placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan 100 mg vs placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sumatriptan 50‐85 mg plus naproxen 500 mg vs placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.2</p> </td> </tr> </tbody> </table> </div> </p> <p>The results, for this outcome, of the sumatriptan plus naproxen combination show the additivity of pain‐relieving drugs demonstrated in several acute pain conditions including migraine (<a href="./references#CD008541-bbs2-0057" title="MooreRA , DerryCJ , DerryS , StraubeS , McQuayHJ . A conservative method of testing whether combination analgesics produce additive or synergistic effects using evidence from acute pain and migraine. European Journal of Pain2012;16(4):585-91. [DOI: 10.1016/j.ejpain.2011.08.009]">Moore 2012</a>). The combination produced lower (better) NNT values versus placebo for the outcome of headache relief at two hours than did sumatriptan or naproxen alone. Adverse event experiences were similar for sumatriptan alone and in combination. </p> <p><a href="./references#CD008541-bbs2-0066" title="SuthisisangCC , PoolsupN , SuksomboonN . Efficacy and safety of sumatriptan plus naproxen sodium in the acute treatment of migraine: systematic review and meta-analysis of randomized controlled trials. Internet Journal of Pain, Symptom Control and Palliative Care2011;8:2. [DOI: 10.5580/6a2]">Suthisisang 2011</a> is a meta‐analysis of three of the 12 studies included in this review (<a href="./references#CD008541-bbs2-0001" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 1</a>; <a href="./references#CD008541-bbs2-0002" title="BrandesJL , KudrowD , StarkSR , O'CarrollCP , AdelmanJU , O'DonnellFJ , et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA2007;297(13):1443-54. [DOI: 10.1001/jama.297.13.1443]LandyS , DeRossettSE , RapoportA , RothrockJ , AmesMH , McDonaldSA , et al. Two double-blind, multicentre, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: function, productivity and satisfaction outcomes. Medscape General Medicine2007;9(2):53. ">Brandes 2007 Study 2</a>; <a href="./references#CD008541-bbs2-0012" title="SmithTR , SunshineA , StarkSR , LittlefieldDE , SpruillSE , AlexanderWJ . Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache2005;45(8):983-91. [DOI: 10.1111/j.1526-4610.2005.05178.x]">Smith 2005</a>). The meta‐analysis quotes NNT values for sumatriptan plus naproxen versus sumatriptan monotherapy of 10 (95% CI 8 to 17) for pain‐free at two hours, 10 (8 to 15) for sustained pain‐free during the 24 hours post dose, 10 (7 to 17) for headache relief at two hours, and 8 (6 to 13) for sustained headache relief during the 24 hours post dose. These are the only studies that allow comparisons between the combination and sumatriptan monotherapy, and the results from the meta‐analysis in <a href="./references#CD008541-bbs2-0066" title="SuthisisangCC , PoolsupN , SuksomboonN . Efficacy and safety of sumatriptan plus naproxen sodium in the acute treatment of migraine: systematic review and meta-analysis of randomized controlled trials. Internet Journal of Pain, Symptom Control and Palliative Care2011;8:2. [DOI: 10.5580/6a2]">Suthisisang 2011</a> are consistent with the results reported in this review for the same comparison with the same studies. </p> <p><a href="./references#CD008541-bbs2-0045" title="KhouryCK , CouchJR . Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal. Drug Design, Development and Therapy2010;4:9-17. [PMID: 20368903]">Khoury 2010</a> reviewed various aspects of the combination therapy including mode of action, pharmacokinetics, and efficacy, but no data synthesis was carried out. A combined analysis of two randomised studies reported on the composite endpoint of sustained pain‐free with no adverse events (<a href="./references#CD008541-bbs2-0017" title="LandyS , WhiteJ , LenerSE , McDonaldSA . Fixed-dose sumatriptan/naproxen sodium compared with each monotherapy utilizing the novel composite endpoint of sustained pain-free/no adverse events. Therapeutic Advances in Neurological Disorders2009;2(3):135. [DOI: 10.1177/1756285609102769]">Landy 2009</a>); this showed that with a composite endpoint sumatriptan plus naproxen was significantly better than placebo or either component alone. </p> <p>A randomised, double‐blind, active‐controlled trial using the combination treatment and the individual monotherapies looked at the primary endpoint of changes in blood pressure from baseline over a six‐month period (<a href="./references#CD008541-bbs2-0020" title="WhiteW , DeposierF , ThompsonA , AdamsB , GoodmanD . Evaluation of the migraine treatment sumatriptan/naproxen on blood pressure following long term administration. Journal of Clinical Hypertension2011;13(12):910-6. ">White 2011</a>), but with no efficacy or adverse event data relating to single migraine episodes. This showed no clinically significant blood pressure changes, and also allowed some analysis of longer‐term adverse events. In particular, the study showed that the type of adverse events were broadly similar over this longer time scale, and that the proportions of adverse events with each therapy (20%, 29%, and 18% for combination, sumatriptan alone, and naproxen alone, respectively) in <a href="./references#CD008541-bbs2-0020" title="WhiteW , DeposierF , ThompsonA , AdamsB , GoodmanD . Evaluation of the migraine treatment sumatriptan/naproxen on blood pressure following long term administration. Journal of Clinical Hypertension2011;13(12):910-6. ">White 2011</a> were equivalent to those seen here in single‐episode analyses (21%, 26%, and 15% for combination, sumatriptan alone, and naproxen alone, respectively, in participants with moderate to severe baseline pain). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008541-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD008541-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/full#CD008541-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008541-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/full#CD008541-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Sumatriptan plus naproxen versus placebo, outcome: 1.1 Pain‐free at two hours." data-id="CD008541-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Sumatriptan plus naproxen versus placebo, outcome: 1.1 Pain‐free at two hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/full#CD008541-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-FIG-04" target="_blank"><b></b></a></p> </div><img alt="L'Abbé plot showing results for sumatriptan plus naproxen versus placebo for pain‐free at two hours. Each circle represents a different study; blue circles are studies with moderate or severe baseline pain and cream circles are mild baseline pain; size of circle is proportional to size of study; diagonal is line of equivalence." data-id="CD008541-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-FIG-04.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>L'Abbé plot showing results for sumatriptan plus naproxen versus placebo for pain‐free at two hours. Each circle represents a different study; blue circles are studies with moderate or severe baseline pain and cream circles are mild baseline pain; size of circle is proportional to size of study; diagonal is line of equivalence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/full#CD008541-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-FIG-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Sumatriptan plus naproxen versus placebo, outcome: 1.2 Headache relief at two hours." data-id="CD008541-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Sumatriptan plus naproxen versus placebo, outcome: 1.2 Headache relief at two hours. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/full#CD008541-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-FIG-06" target="_blank"><b></b></a></p> </div><img alt="L'Abbé plot showing results for sumatriptan plus naproxen versus placebo for headache relief at two hours in studies with moderate or severe baseline pain. Each circle represents a different study; size of circle is proportional to size of study; diagonal is line of equivalence." data-id="CD008541-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-FIG-06.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>L'Abbé plot showing results for sumatriptan plus naproxen versus placebo for headache relief at two hours in studies with moderate or severe baseline pain. Each circle represents a different study; size of circle is proportional to size of study; diagonal is line of equivalence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/full#CD008541-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-FIG-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-FIG-07" target="_blank"><b></b></a></p> </div><img alt="L'Abbé plot showing results for sumatriptan plus naproxen versus placebo for 24‐hour sustained pain‐free. Each circle represents a different study; blue circles are studies with moderate or severe baseline pain and cream circles are mild baseline pain; size of circle is proportional to size of study; diagonal is line of equivalence." data-id="CD008541-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-FIG-07.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>L'Abbé plot showing results for sumatriptan plus naproxen versus placebo for 24‐hour sustained pain‐free. Each circle represents a different study; blue circles are studies with moderate or severe baseline pain and cream circles are mild baseline pain; size of circle is proportional to size of study; diagonal is line of equivalence. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/full#CD008541-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-FIG-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Sumatriptan plus naproxen versus placebo, Outcome 1: Pain‐free at 2 h" data-id="CD008541-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Sumatriptan plus naproxen versus placebo, Outcome 1: Pain‐free at 2 h </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#CD008541-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Sumatriptan plus naproxen versus placebo, Outcome 2: Headache relief at 2 h" data-id="CD008541-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Sumatriptan plus naproxen versus placebo, Outcome 2: Headache relief at 2 h </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#CD008541-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Sumatriptan plus naproxen versus placebo, Outcome 3: 24‐h sustained pain‐free" data-id="CD008541-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Sumatriptan plus naproxen versus placebo, Outcome 3: 24‐h sustained pain‐free </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#CD008541-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Sumatriptan plus naproxen versus placebo, Outcome 4: 24‐h sustained headache relief" data-id="CD008541-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Sumatriptan plus naproxen versus placebo, Outcome 4: 24‐h sustained headache relief </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#CD008541-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Sumatriptan plus naproxen versus placebo, Outcome 5: Any adverse event" data-id="CD008541-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Sumatriptan plus naproxen versus placebo, Outcome 5: Any adverse event</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#CD008541-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Sumatriptan plus naproxen versus placebo, Outcome 6: Rescue medication" data-id="CD008541-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Sumatriptan plus naproxen versus placebo, Outcome 6: Rescue medication</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#CD008541-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Sumatriptan plus naproxen versus placebo, Outcome 7: Relief of associated symptoms at 2 h" data-id="CD008541-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Sumatriptan plus naproxen versus placebo, Outcome 7: Relief of associated symptoms at 2 h </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#CD008541-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Sumatriptan plus naproxen versus placebo, Outcome 8: Relief of functional disability at 2 h" data-id="CD008541-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Sumatriptan plus naproxen versus placebo, Outcome 8: Relief of functional disability at 2 h </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#CD008541-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sumatriptan plus naproxen versus sumatriptan alone, Outcome 1: Pain‐free at 2 h" data-id="CD008541-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Sumatriptan plus naproxen versus sumatriptan alone, Outcome 1: Pain‐free at 2 h </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#CD008541-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sumatriptan plus naproxen versus sumatriptan alone, Outcome 2: Headache relief at 2 h" data-id="CD008541-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Sumatriptan plus naproxen versus sumatriptan alone, Outcome 2: Headache relief at 2 h </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#CD008541-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sumatriptan plus naproxen versus sumatriptan alone, Outcome 3: 24‐h sustained pain‐free" data-id="CD008541-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Sumatriptan plus naproxen versus sumatriptan alone, Outcome 3: 24‐h sustained pain‐free </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#CD008541-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sumatriptan plus naproxen versus sumatriptan alone, Outcome 4: 24‐h sustained headache relief" data-id="CD008541-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Sumatriptan plus naproxen versus sumatriptan alone, Outcome 4: 24‐h sustained headache relief </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#CD008541-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sumatriptan plus naproxen versus sumatriptan alone, Outcome 5: Any adverse event" data-id="CD008541-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Sumatriptan plus naproxen versus sumatriptan alone, Outcome 5: Any adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#CD008541-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sumatriptan plus naproxen versus sumatriptan alone, Outcome 6: Rescue medication" data-id="CD008541-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Sumatriptan plus naproxen versus sumatriptan alone, Outcome 6: Rescue medication </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#CD008541-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sumatriptan plus naproxen versus sumatriptan alone, Outcome 7: Relief of associated symptoms at 2 h" data-id="CD008541-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Sumatriptan plus naproxen versus sumatriptan alone, Outcome 7: Relief of associated symptoms at 2 h </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#CD008541-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sumatriptan plus naproxen versus sumatriptan alone, Outcome 8: Relief of functional disability at 2 h" data-id="CD008541-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Sumatriptan plus naproxen versus sumatriptan alone, Outcome 8: Relief of functional disability at 2 h </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#CD008541-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sumatriptan plus naproxen versus naproxen alone, Outcome 1: Pain‐free at 2 h" data-id="CD008541-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Sumatriptan plus naproxen versus naproxen alone, Outcome 1: Pain‐free at 2 h </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#CD008541-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sumatriptan plus naproxen versus naproxen alone, Outcome 2: Headache relief at 2 h" data-id="CD008541-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Sumatriptan plus naproxen versus naproxen alone, Outcome 2: Headache relief at 2 h </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#CD008541-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sumatriptan plus naproxen versus naproxen alone, Outcome 3: 24‐h sustained pain‐free" data-id="CD008541-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Sumatriptan plus naproxen versus naproxen alone, Outcome 3: 24‐h sustained pain‐free </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#CD008541-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sumatriptan plus naproxen versus naproxen alone, Outcome 4: 24‐h sustained headache relief" data-id="CD008541-fig-0027" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Sumatriptan plus naproxen versus naproxen alone, Outcome 4: 24‐h sustained headache relief </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#CD008541-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sumatriptan plus naproxen versus naproxen alone, Outcome 5: Any adverse event" data-id="CD008541-fig-0028" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Sumatriptan plus naproxen versus naproxen alone, Outcome 5: Any adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#CD008541-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sumatriptan plus naproxen versus naproxen alone, Outcome 6: Rescue medication" data-id="CD008541-fig-0029" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Sumatriptan plus naproxen versus naproxen alone, Outcome 6: Rescue medication</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#CD008541-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sumatriptan plus naproxen versus naproxen alone, Outcome 7: Relief of associated symptoms at 2 h" data-id="CD008541-fig-0030" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Sumatriptan plus naproxen versus naproxen alone, Outcome 7: Relief of associated symptoms at 2 h </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#CD008541-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008541-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/urn:x-wiley:14651858:media:CD008541:CD008541-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sumatriptan plus naproxen versus naproxen alone, Outcome 8: Relief of functional disability at 2 h" data-id="CD008541-fig-0031" src="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_t/tCD008541-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Sumatriptan plus naproxen versus naproxen alone, Outcome 8: Relief of functional disability at 2 h </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#CD008541-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/media/CDSR/CD008541/image_n/nCD008541-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008541-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Sumatriptan 50 mg or 85 mg plus naproxen 500 mg compared with placebo for migraine headache</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Sumatriptan 50 mg or 85 mg plus naproxen 500 mg compared with placebo for migraine headache</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: adults with migraine headache ‐ moderate or severe and mild baseline pain</b> </p> <p><b>Settings: community</b> </p> <p><b>Intervention: sumatriptan 50 mg or 85 mg plus naproxen 500 mg</b> </p> <p><b>Comparison: placebo</b> </p> </td> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Probable outcome with</b> <br/><b>comparator</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>Probable outcome with</b> <br/><b>intervention</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>NNT or NNH</b> <br/><b>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>No. of studies, attacks, events</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain‐free response at 2 h for moderate to severe baseline pain</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.7 (2.8 to 4.5)</p> <p>NNT 4.9 (4.3 to 5.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies, 2596 attacks, 462 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate numbers of studies and attacks, study quality good, consistency of response</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain‐free response at 2 h for mild baseline pain</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>180 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.8 (2.4 to 3.1)</p> <p>NNT 3.1 (2.9 to 3.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 studies, 3395 attacks, 1252 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate numbers of studies and attacks, study quality good, consistency of response</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Headache relief at 2 h for moderate to severe baseline pain</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>270 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>580 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.2 (2.0 to 2.4)</p> <p>NNT 3.2 (2.9 to 3.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies, 2596 attacks, 1107 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate numbers of studies and attacks, study quality good, consistency of response</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sustained pain‐free during the 24 h post dose for moderate to severe baseline pain</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.4 (2.7 to 4.4)</p> <p>NNT 7.9 (5.9 to 8.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies, 2596 attacks, 339 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate numbers of studies and attacks, study quality good, consistency of response. Downgraded because of threat from potential publication bias with modest effect size and modest number of events </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sustained pain‐free during the 24 h post dose for mild baseline pain</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>370 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.0 (2.6 to 3.6)</p> <p>NNT 4.1 (3.7 to 4.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 studies, 3396 attacks, 907 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate numbers of studies and attacks, study quality good, consistency of response</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sustained headache relief during the 24 h post dose for moderate or severe baseline pain</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>160 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>430 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.6 (2.3 to 3.0)</p> <p>(NNT 3.8 (3.4 to 4.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies, 2596 attacks, 768 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate numbers of studies and attacks, study quality good, consistency of response</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>At least 1 AE during treatment for moderate to severe baseline pain</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>210 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.0 (1.6 to 2.4)</p> <p>NNH 11 (8.3 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 studies, 2793 attacks, 465 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate numbers of studies and attacks, study quality good, consistency of response. Downgraded because of threat from potential publication bias with modest effect size </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>At least 1 AE during treatment for mild baseline pain</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 in 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>140 in 1000</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.5 (1.2 to 1.9)</p> <p>NNH 18 (13 to 30)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 studies, 2823 attacks, 329 events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adequate numbers of studies and attacks, study quality good, consistency of response. Downgraded because of threat from potential publication bias with modest effect size and modest number of events </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious AE (all levels of baseline pain)</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 event possibly related to intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>AE:</b> adverse event; <b>CI:</b> confidence interval; <b>NNT:</b> number needed to treat for an additional beneficial outcome; <b>NNH:</b> number needed to treat for an additional harmful outcome; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Sumatriptan 50 mg or 85 mg plus naproxen 500 mg compared with placebo for migraine headache</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/full#CD008541-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008541-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Sumatriptan plus naproxen versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Pain‐free at 2 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Mild baseline pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.76 [2.43, 3.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Moderate/severe baseline pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.65 [2.97, 4.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Headache relief at 2 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Moderate/severe baseline pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.16 [1.95, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 24‐h sustained pain‐free <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Mild baseline pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.04 [2.59, 3.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Moderate/severe baseline pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.43 [2.69, 4.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 24‐h sustained headache relief <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Moderate/severe baseline pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.61 [2.27, 2.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5616</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [1.53, 2.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Mild baseline pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2823</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [1.16, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Moderate/severe baseline pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2793</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.97 [1.64, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Rescue medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5565</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.41, 0.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Mild baseline pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.38, 0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Moderate/severe baseline pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.42, 0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Relief of associated symptoms at 2 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1705</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.47 [2.79, 4.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Photophobia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.77 [2.44, 3.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 Phonophobia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2856</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.63 [2.33, 2.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Relief of functional disability at 2 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Mild baseline pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.91 [2.29, 3.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Moderate/severe baseline pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.36 [2.63, 4.29]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Sumatriptan plus naproxen versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#CD008541-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008541-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Sumatriptan plus naproxen versus sumatriptan alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Pain‐free at 2 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1925</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [1.23, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Headache relief at 2 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1925</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [1.11, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 24‐h sustained pain‐free <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1925</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.41, 2.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 24‐h sustained headache relief <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1925</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [1.24, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1952</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.86, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Rescue medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1925</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.58, 0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Relief of associated symptoms at 2 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [1.21, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 Photophobia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [1.04, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.3 Phonophobia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [1.10, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Relief of functional disability at 2 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [1.18, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Sumatriptan plus naproxen versus sumatriptan alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#CD008541-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008541-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Sumatriptan plus naproxen versus naproxen alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Pain‐free at 2 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1944</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.03 [1.71, 2.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Headache relief at 2 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1944</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [1.30, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 24‐h sustained pain‐free <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1944</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [1.82, 2.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 24‐h sustained headache relief <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1944</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [1.45, 1.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.47, 2.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Rescue medication <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1944</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.54, 0.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Relief of associated symptoms at 2 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.90, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.2 Photophobia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [1.19, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.3 Phonophobia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.28, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Relief of functional disability at 2 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [1.35, 1.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Sumatriptan plus naproxen versus naproxen alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008541.pub3/references#CD008541-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008541.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD008541-note-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD008541-note-0010">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008541-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD008541-note-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD008541-note-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD008541-note-0009">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD008541-note-0005">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD008541-note-0004">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008541\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008541\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008541\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008541\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008541\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008541\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008541\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008541\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008541\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008541\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008541\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008541\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008541\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008541\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008541\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008541\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008541\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008541\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=VXKc2U6b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008541.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008541.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008541.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008541.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008541.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716391417"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008541.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716391421"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008541.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d9e5fa8f09368',t:'MTc0MDcxNjM5MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 